XXXXXXXX XXXXXX X XXXXXXXXX XXXXXXXXX (XX) x. 1062/2014
xx xxx 4. xxxxx 2014,
týkající xx xxxxxxxxxx xxxxxxxx xxxxxxxxxxxxxx xxxxxxxx všech xxxxxxxxxxx xxxxxxxx xxxxx xxxxxxxxxx x xxxxxxxxxx přípravcích, které xxxx uvedeny x xxxxxxxx Xxxxxxxxxx parlamentu x Xxxx (XX) x. 528/2012
(Xxxx x xxxxxxxx xxx XXX)
XXXXXXXX XXXXXX,
x xxxxxxx xx Xxxxxxx x xxxxxxxxx Evropské xxxx,
x xxxxxxx xx xxxxxxxx Evropského parlamentu x Rady (XX) x. 528/2012 ze xxx 22. xxxxxx 2012 x xxxxxxxx xxxxxxxxxx přípravků xx xxx x xxxxxx xxxxxxxxx (1), x xxxxxxx xx xx. 89 xxxx. 1 xxxxx xxxxxxxxxxx xxxxxxxxx xxxxxxxx,
xxxxxxxx x xxxxx důvodům:
|
(1) |
Xxxxxxxx Xxxxxx (XX) č. 1451/2007 (2) xxxxxxx xxxxxxxxx xxxxxxxx xxx xxxxxxx xxxxxxxx xxxxxxxxxxx biocidních xxxxxxxx xxxxx (xxxx jen „xxxxxxx přezkumu“), xxxxx xxx xxxxxxx v souladu x xx. 16 xxxx. 2 xxxxxxxx Xxxxxxxxxx parlamentu x Xxxx 98/8/XX (3). Protože xxxx xxxxxxxx xxxx zrušena x xxxxxxxxx nařízením (XX) x. 528/2012, xxxx xx xxx xxxxxxxxx pravidla xxx xxxxxxxxxxx xxxxxxxx xxxxxxxx xxxxxxxxxxxx xxxxxxxxxxx xxxxxxxxx xxxxxxxx. |
|
(2) |
Xx důležité xxxxx xxxxxxxxx účinné xxxxx x xxxx xxxxxxxxx, které mohou xxx xxxxxxxx na trh x xxxxxxxxx xxxxx xxxxxxxxxxx xxxxxxxxxx xxxxxx 89 nařízení (XX) x. 528/2012 x xxxxxxxx xxxxxxxxxxxxxx xxxxxxxx. Mělo xx xxxx být x v případě xxxxxxxxx xxxxxx xxxxx x xxxx přípravku, xxxxx xxxx hodnoceny x programu přezkumu. |
|
(3) |
Pokud xxxxxxxxx xxxxxxxx xxxxxxxx xxx xxxxxxxxx x xxxxxx xxxxx xxxxxx 6 xxxxxxxx (XX) x. 1451/2007, xxx nevztahuje xx xx xxx xxxxxxx xxx potraviny x xxxxxx xxxxxxx x xx. 2 xxxx. 5 xxxx. x) nařízení (XX) x. 528/2012, xxxx by xxx účinné látky, xxxxx xxxxxxxx, xxxxxxxxx x xxxxxxxx přezkumu xxx xxxxxxxxx typ xxxxxxxxx. X xxxxxxxx xxxxxxxxxxxxxx předpisů xx xxxx xxx xxxxxx xxxxxxxx xx xxx x xxxxxxxxx umožněno xx xx xxxxxxxx xxxxxxxxx xxxxxxxxx. Xxxxxx xxxxxxxxxxx xxxxxxxxxx xx xxx vymezit, xxxxx přípravky xxxxxx xxxxxxxxxx xxxxxxx. Xxxxx xx mělo xxxxxx x xxxxxxxxx, xxx xxxxxxxxxx xxxxxxxxx xxxxxx xxxxx x xxxx xxxxxxxxx xxxxxxxxx x xxxx xxxxxxxx xxxx xxxxxxxxx x xxxxxxxx (XX) x. 528/2012 oproti xxxxxxxx uvedené xx xxxxxxxx 98/8/XX xxxx xx xxxxx xxxxxxxxxx xxxxxxxxxxx Xxxxxx přijatým x xxxxxxx x xx. 3 xxxx. 3 xxxxxxxx (XX) x. 528/2012, xxxxxxxxxxx (xxxxxxxxx xxxxxxxxxxx xx věci C-420/10 (4)) xxxx xxxxxxxxx xxxxxx Xxxxxx xx xxxxxxxxxxx xxxxxx xxxxxxxxx xxxxx, xxxxx xx xxxxxxxx xxxxxxx. |
|
(4) |
Xxxxx biocidní xxxxxxxxx xxxxxxxx účinnou látku, xxxxx již xxxx xxxxxxxx xx xxxxxxxx xxxxxxxx, x xxxx xxxxx xxxxxxx xxxx xx z xx xxxxxx, xxxxx xxxxxxxx xx xxxxxxxxx xxxxxx xxxxxxxxxx přípravku x xxxxxxxx xxxxx nezbytné, xxxx xx xxx x xxxxx xxxxxxxx xxxxx xxxxxxx x dodávání xx xxx xxxxxxxx xx xxxx xxxxxxxxxxxx, xx xxxxxxxx xxxxxxxx x xx omezenou xxxx. |
|
(5) |
X xxxxx jednotnosti x xxxxxxxxxxxx xx měl xxx xxxxxx hodnocení xxxxxxxx xxxxx x xxxxxxxx xxxxxxxx ve všech xxxxxxxxxx částech totožný x postupem xxxxxxxxxx xxx xxxxxxx xxxxxxxxxx xxxxx xxxxxx 7 xxxxxxxx (XX) x. 528/2012 xxxx xxxxx xxxxxxxxxxx xxxxxxxx Xxxxxx (EU) x. 88/2014 (5). |
|
(6) |
Xxx xxxxx, xxxxx xxxxxxx xxxxxxxx xxxxxxxxx xxxx xxxxxxxx xxx xxxxxxx, xx xxx xxxxxxxxx xxxxxxxxx xxxxx xxxxxxxxx xxxxxxxx návrh harmonizované xxxxxxxxxxx x xxxxxxxx xxxxx xxxxx čl. 37 odst. 1 xxxxxxxx Xxxxxxxxxx parlamentu x Xxxx (XX) x. 1272/2008 (6), xxxxx jde o xxxxxxxxx xxxxxxxxxx xxxxxxxxxx xxxxx, a zároveň xx xxxx xxx xxxxxxxxx xxxxx členského xxxxx xxxxxxxxx xxxxx xxxxxxxx xx xxxxxx xxxx xxxxx sledovaných vlastností. Xxxxxxxxx xxxxxxxxx xxxxx xx xxx xxxx xxxxxxxxxxx agenturu x xxxxxxx xxxxx, které xx splňovaly xxxxxxxx xxx xxxxx perzistentní, xxxxxxxxxxxxxxx xx xxxxxxx, xxxx xxxxx, xxxxx xx xxxxx xxx xxxxxxxxxx xx xxxxx x xxxxxxxxxxx xxxxxxxxxxxxxx xxxxxxxx xxxxxxxxxx xxxxxxxx. |
|
(7) |
Xxx xxxx xxxxxxxxx, xx program přezkumu xxxx xxxxxxxx do xxxxxxxx xxxx uvedeného x xx. 89 xxxx. 1 xxxxxxxx (XX) x. 528/2012, xxxx xx xx hodnocení xxxxxx xx xxxxxxxxx xxxxxx xxxxx a typu xxxxxxxxx, u xxxxx xxxx příslušné údaje xxxxxxxxxx xx xxxxxxx stanovených x xxxxxxxx (XX) č. 1451/2007 xxxx x xxxxx nařízení. Xxxxx toho xx xx měly xxxxxxxx xxxxxx xxxxx pro xxxxxxxxx hodnocení, xxxxxxx xx xx xxxx xxxx x xxxxx xxxxxxx, xx xxxxxxx xx mohly xxx xxxxxxxxx xxxx xxx xxx před xxxxxxxxx xxxxxx xxxx. |
|
(8) |
Ohledně zařazení xx xxxxxxx X xxxxxxxxx 7 xxxxxxxx (XX) č. 528/2012 xxxxx xxxxxx stanoveny xxxxx xxxxxxxxx xx xxxxx. Xx xxxxx vhodné x xxxx xxxx xxxxxx xxxxxxx o zařazení xx xxxxxxx přílohy xx kategorie 1, 2, 3, 4, 5 xxxx 6. |
|
(9) |
Xxx xxxxxx xx xx. 90 xxxx. 2 xxxxxxxx (EU) č. 528/2012 xxxxxxx x xxxxxx 91 xxxxxxxxx nařízení, že xxxxxxxx xxxxxxx x xxxxxx 10 xxxxxxxxx nařízení xx xxxx být xxxxxxxxxx xxx xxxxxxxx xxxxxxxxxx xxxxxxxxxx xxxxxxxxx xx xxxxx xxxxxxxxx. Xx xxxxx xxxxxx xxxxx látky xxxxxxxxx xxxx xxxxxxxx xx xxxxx xxxxxxxxxxx účinných xxxxx. |
|
(10) |
Xxxxxxxxxxx xxxxxxxx programu xxxxxxxx by xxx xxx možnost se xx xxxxxxxx dohodě xxxxxxxx xx xxxxxxxxxxx xxxxxxxxxxx xxxx xxx xxxxxxxx xx xxxxxxxxxxx, xx xxxxx tomu xxxxxxx ke xxxxxxxx xxxxxxxxx x xxxxxx xxxxxxxxx xxxxxxxx k xxxxxx, xxxxxxx xxxxx xx xxxxxxxxxxx xxxxxxxx xxxxx xxxxxxxxx údaje xxxxx. |
|
(11) |
Xxxxxxx xx účast x xxxxxxxx xxxxxxxx xxxxxxxxxx, xxxx xx xxx účastníkům xxxxxxxx od ní xxxxxxxxx. Xxxxx k xxxx xxxxx, xxxx xx xxx xxxxxxxxxxx xxxxxxxxx xxxxxxx převzít xxxxxxx, xxxxxx-xx xxxx xxxxxxxx využito xxx xxxxxx, xxxxx xxx xxxxxxx xx xxxxxxxx xxxxxxxx xxxxxxxx, x xxxxxxxx-xx xxxxxxxx xxx xxxxxxxx na xxxx xxxxxxxxxx. |
|
(12) |
Xxxxx se xxx xxxxxxxxx xxxxxx xxxxx xxxxx, že identita xxxxxxxxx xxxxxxxx xx xxxxxxxx přezkumu xxxxxx xxxxxxxxxx xxxxxxxx xxxxxxxx xxxxxxxxx látky, x x xxxxxxxxx xxxxx xxxxxxx závěry xxxxxxx xxxxxxxx xxxxxxxxx zařazené xxxxx, xxxx by xxx xxxxx tuto xxxxx x xxxxxxx xxxxxxxxx xxxxx xxxxxxxxx x xxxxxxx xxxxx xxxxxx, xxx xxxxxxxx podporu této xxxxxxxxx xxxxxxxx xxxxx. |
|
(13) |
Xxxxxxx xxxxx xxxxxxxx do xxxxxxxx xxxxxxxx xxxxxx x xxxx přijetí xxxxxx nařízení xxxxxxxxxxx xxxxxx účastníkem. Totéž xx xxxx xxxxxxxx xxxxxxxxxxxxx, xxxxxx xxxxx xx. 4 xxxx. 4 xxxxxxxx (XX) x. 528/2012 xxxx xxxxxxxxx nelze schválit, xxxxx xxx xxxx xxxxxxxx xxxxxxxxx. X xxxxxxxxx látek x xxxxxxxxxxxxx xx xxxx xxx xxxxx xxxxxxx xxxxxxx xxxxx, protože xxxxx xx xxxx xxxxx a nanomateriály xxxxxx xxx x programu xxxxxxxx xxxxxxxxx. |
|
(14) |
Xxx xxxx xxxxxxxxx, xx xxxxx xxxxx xxxxxxxxx x xxxxxxxx xxxxxxxxxxx ani xx xxx xxxxxx xxxxxxxx, xxxx xx xxxxxxxx byla xxxxxxxxxxx, xxxx xx xxxxxxxx xxxxx, xxxxx xxxxx xxxxxx xxxxxxxxx, v xxxxxxxx nebo xxxx xxxxxxxx xxxxxxxx xxxxxxxxxx xxxxxxxxxx xxxxx o xx, |
XXXXXXX XXXX XXXXXXXX:
KAPITOLA 1
PŘEDMĚT X XXXXXXXX
Xxxxxx 1
Xxxxxxx
Xxxx xxxxxxxx xxxxxxx xxxxxxxx xxx xxxxxxxxx pracovního xxxxxxxx xxxxxxxxxxxxxx xxxxxxxx všech xxxxxxxxxxx xxxxxxxx xxxxx xxxxxxxxx v článku 89 xxxxxxxx (XX) x.&xxxx;528/2012.
Xxxxxx 2
Xxxxxxxx
Pro xxxxx xxxxxx xxxxxxxx xx xxxxxxx xxxx xxxxxxxx:
|
x) |
„xxxxxxxxxxx x xxxxxxxxxxx“ xx xxxxxx xxxxxxxxxx xxxxxxxxxx xxxxxxxxx látky x xxxx xxxxxxxxx xxxxx xx. 9 xxxx. 1 xxxx. x) nařízení (XX) č. 528/2012 nebo xx. 89 xxxx. 1 xxxxxxx xxxxxxxxxxx xxxxxxxxx xxxxxxxx, xxxx xxxxxxxxx nezařadit xx xxxxxxx X xxxx XX xxxxxxxx 98/8/ES; |
|
x) |
„xxxxxxxxx látky x xxxx přípravku zařazenou xx xxxxxxxx xxxxxxxx“ se xxxxxx xxxxxxxxx xxxxx x xxxx xxxxxxxxx xxxxxxx x xxxxxxx XX, xxxxx xxxxxxx xxxx podmínky:
|
|
x) |
„xxxxxxxxxx“ se xxxxxx xxxxx, která xxxxxxxxxx xxxxxx o xxxxxxxxx xxxxx x xxxx xxxxxxxxx xxxxxxxx xx xxxxxxxx xxxxxxxx nebo xxxxxxxxxx xxxxxxxx, xxxxx xxxxxxxx xxxxxxxxxx xxxxx xx. 17 xxxx. 5 xxxxxx nařízení, xxxx xxxxxx xxxxxx xxxx xxxx žádost xxxx oznámení xxxxxxxxxx; |
|
x) |
„hodnotícím xxxxxxxxxx xxxxxxx“ xx xxxxxx xxxxxxxxx xxxxx xxxxxxxxx xxxxx xxxxxxxxx x příloze II xxxxxx xxxxxxxx, xxxxxx x xxxxxxx x xxxxxxx 81 xxxxxxxx (XX) x. 528/2012. |
KAPITOLA 2
XXXXXX XXXXXXXXX XXXXXXXXXXX
Xxxxxx 3
Xxxxxx x xxxxxxxxx xxxx zařazení xx přílohy X xxxxxxxx (XX) č. 528/2012
1.&xxxx;&xxxx;&xxxx;Xxxxxx x&xxxx;xxxxxxxxx xx xxxxxxxx do přílohy X&xxxx;xxxxxxxx (XX) x.&xxxx;528/2012 xxxx xxxxx pouze xxxxxxxx, x xxxxx oznámení xxxxx xxxxxxxx k xxxxxx, že xxxxxxxx xxxxxxxxxx podle xx.&xxxx;17 xxxx.&xxxx;5 tohoto xxxxxxxx.
Xxxxx xx xxxxxx týká xxxxxxxx do přílohy X&xxxx;xxxxxxxx (XX) x.&xxxx;528/2012, xxxx xx xxxxx pouze xxxxxxxxx 1, 2, 3, 4, 5 xxxx 6 uvedené xxxxxxx.
2.&xxxx;&xxxx;&xxxx;Xxxxxxx uvedené x&xxxx;xxxxxxxx 1 xx xxxxxxxx xxxxxxxx xx&xxxx;xxxx xxx xx xxxxxxxxxx x&xxxx;xxxxxxx x požadavky xxxxx xx.&xxxx;17 xxxx.&xxxx;5.
Xxxxxx 4
Přijetí xxxxxxx
1. Xxxxxxxx xxxxxxxxx xxxxxxxxx o xxxxxxxx splatném xxxxx xxxxxxxxxxx xxxxxxxx Xxxxxx (XX) x. 564/2013 (7) x xxxxxxx žádost, xxxxx účastník nezaplatí xxxxxxxx xx xxxxx 30 xxx. O xxxx xxxxxxxxxxx xxxxxxxxx xxxxxxxxx x hodnotící xxxxxxxxx xxxxx.
2. Xx obdržení xxxxxxxx splatných xxxxx xxxxxxxxxxx nařízení (XX) x. 564/2013 xxxxxx xxxxxxxx žádost a informuje x xxx účastníka x xxxxxxxxx xxxxxxxxx xxxxx, xxxxxxx uvede xxxxx xxxxxxx xxxxxxx x xxxx xxxxxxxxx identifikační xxx.
3. Proti xxxxxxxxxxx xxxxxxxx podle xxxxxxxx 1 tohoto xxxxxx xxx podat xxxxxxx xxxxxxxxxx v xxxxxxx x xxxxxxx 77 xxxxxxxx (XX) x. 528/2012.
4. Xxxxxxxxx xxxxxxxxx xxxxx informuje účastníka x xxxxxxxx splatném xxxxx čl. 80 xxxx. 2 xxxxxxxx (XX) x. 528/2012 xx 30 xxx xxxx, xx agentura xxxxxxx žádost, x xxxxxxx xxxxxx, pokud xxxxxxxx nezaplatí xxxxxxxx xx xxxxx 30 xxx. O xxxx xxxxxxxxxxx xxxxxxxxx xxxxxxxxx x xxxxxxxx.
Xxxxxx 5
Potvrzení xxxxxxx x xxxxxxxxx xxxx xxxxxxxx do kategorie 6 přílohy I xxxxxxxx (XX) x. 528/2012
1. Xxxxx agentura přijme xxxxx xx. 4 xxxx. 2 žádost x xxxxxxxxx xxxx xxxxxxxx xx xxxxxxxxx 6 přílohy X xxxxxxxx (XX) x. 528/2012, xxxxx obsahuje xxxxx xxxxxxxxxx x xxxxxxx x xx. 6 xxxx. 1 x 2 xxxxxxxxx xxxxxxxx, a byl xxxxxxxx xxxxxxxx podle xx. 4 xxxx. 4, hodnotící xxxxxxxxx xxxxx žádost xxxxxxx xx 30 dnů xx zaplacení xxxxxxxx.
2. Xxxxx xxxxxxxxx xxxxxxxxx xxxxx xxxxxxx xx xxxxxxxxx xxxxxxxxxxx xxxxx nařízení (XX) x. 1451/2007, xxxxx xx xxxxx xxxxxx xxxxxx xxxx úplná podle xxxxxx 13 xxxxxxxxx xxxxxxxx, xxxxxxx xxxxxxxxx xxxxxxxxx xxxxx xxxxxx xxxxxxxxxx xx 3. xxxxx 2015.
3. X případech uvedených x xxxxxxxxxx 1 x 2 xxxxxxxxx xxxxxxxxx xxxxx xxxxxxxxx xxxxxxxxx kvality xxx xxxxxxxxxxxx xxxxxxxxxxxx xxxxx xxxx xxxxxxxxxx.
4. Pokud xxxxxxxxx xxxxxxxxx orgán xxxxxx, xx xxxxxx xx xxxxxxx, xxxxx účastníkovi, xxxx xxxxxxxxxx xxxxxxxxx xxxx x xxxxxxxxx xxxxxxx xxxxx, a x předložení xxxxxx xxxxxxxxx xxxxxxx xxxxxxxxxx xxxxx. Tato lhůta xxxxx nepřesáhne 90 xxx.
Xxxxxxxx-xx xxxxxxxxx xxxxxxxxx xxxxx, xx předložené xxxxxxxxxx xxxxxxxxx xxxxxxxxx ke xxxxxxx xxxxxxxxx uvedených x xxxxxxxx 2, xxxxxxx xxxxxx do 30 dnů xx xxxxxxxx xxxxxxxxxxxx informací.
Xxxxxxxx xxxxxxxx xxxxxxxxxx xxxxxxxxx xx xxxxxxxxx lhůtě xxxxxxxxxx, xxxxxxxxx příslušný xxxxx xxxxxx xxxxxxx x xxxxxxxxx o xxxx skutečnosti xxxxxxxxx x xxxxxxxx. X xxxxxx případech xx xxxxx xxxxxxxx zaplacené x xxxxxxx x xx. 80 xxxx. 1 x 2 nařízení (EU) x. 528/2012.
Xxx xxxxxxxxx xxxxxxx xxxxxxxxx xxxxxxxxx orgán xxxxxxxxxx xxxxxxxxx xxxxxxxxx, xxxxxxxx x xxxxx xxxxxxxxx xxxxxx x xxxxx xxxxx xxxxxx xxxxxxxxx.
Xxxxxx 6
Xxxxxxxxx xxxxxxx
1. Xxxxx xxxxxx se použije, xxxxx xxxxx xxxxxxx x xxxxxx podmínek:
|
x) |
xx-xx xxxxxx xxxxxxxxx podle xxxxxx 5; |
|
x) |
xxxxx xxxxxxxxx xxxxxxxxx xxxxx uznal xxxxxxxxxxx xxxx úplnou xxxxx xxxxxx 13 nařízení (XX) x. 1451/2007, xxx xxxxx xxxxxxxxxxx Xxxxxx zprávu xxxxxxxxxxx xxxxxx podle xx. 14 odst. 4 xxxxxxxxx xxxxxxxx; |
|
x) |
xxxxx xxxxxxxx xxxxxxx xxxxxx x xxxxxxxx xx xxxxxxxxx 1, 2, 3, 4 xxxx 5 xxxxxxx X xxxxxxxx (XX) č. 528/2012 podle xx. 4 xxxx. 2 x xxx xxxxxxxx poplatek xxxxx xx. 4 xxxx. 4. |
2. Hodnotící xxxxxxxxx xxxxx xxxxxxxx xxxxxx podle xxxxxx 4 x 5 xxxxxxxx (XX) x. 528/2012 x xxxxxxxx xxx xxxxxxx xxxxxx xx xxxxxx požadavků xx xxxxx xxxxxxxxxx x xxxxxxx x xx. 6 odst. 3 uvedeného xxxxxxxx x xxxxx xxxxxxxxx xxxxxx a xxxxxx xxxxx hodnocení xxxxxxxx.
3. Xxxxx xxxxxxx xxxxxxxxx látky x xxxx přípravků xxxxxxxxx několik xxxxxxxxx, xxxxxxxxx xxxxxxxxx xxxxxxxxx xxxxx pouze xxxxx xxxxxxxxx zprávu. Xxxxxxxxx xxxxxx x xxxxxx zašle x jedné x xxxxxx xxxx, xxxxx xxxx, xx xxxxxxx xxxxxxx:
|
x) |
365 xxx po posledním xxxxxxxxx uvedeném v odst. 1 xxxx. x), xxxxxx xxxxxxxx xxxxxxxx v odst. 1 xxxx. x) xxxx xxxxxxxxx poplatku xxxxxxxxx x xxxx. 1 xxxx. x) x dotyčné xxxxxxxxx xxxxx x xxxx xxxxxxxxx; |
|
b) |
xx xxxxx stanovené x xxxxxxx XXX. |
4. Xxxx xxx, xxx xxxxxxxxx xxxxxxxxx xxxxx xxxxxxxx xxx xxxxxx xxxxxxxx, xxxxxx xxxxxxxxxxx xxxxx xx 30 xxx k xxxxxxxxx xxxxxx a x xxxxxxx xxxxxxxxx písemné xxxxxxxxxx. Hodnotící xxxxxxxxx xxxxx tyto připomínky xxxxxxxxxxxxx způsobem xxxxxxxx x xxxxxxxxx xxxx xxxxx xxxxxxxxx.
5. Xxxxx xx xxxxx, xx xxxx x xxxxxxxxx xxxxx xxxxxxxxxx informace, xxxxxxxxx xxxxxxxxx xxxxx účastníka xxxxx, xxx tyto xxxxxxxxx ve xxxxxxxxx xxxxx předložil, x xxxxxxxxx x xxx xxxxxxxx.
Xxxxx 365 dnů xxxxxxx x xxxxxxxx 3 se xxxxxxx xx dobu ode xxx vznesení xxxxxxxxx xx xxx xxxxxxxx xxxxxxxxx. Pokud xx xxxx xxxxxxxxxx xxxxxxx xxxxxxxxxxxx xxxxx xxxx xxxxxxxxxxx xxxxxxxxxx, xxxxxxxxx xxxxxxxxxx následující lhůty:
|
x) |
365 xxx x xxxxxxx, že xx doplňující xxxxxxxxx xxxxxx otázek, xxxxx xxxxxx xxxxxx v xxxxx směrnice 98/8/XX xxxx x xxxxx postupů xxxxxxxxxxx pro xxxxxxxxxxx xxxxxxx směrnice; |
|
b) |
180 dní xx xxxxx xxxxxxxxx xxxxxxxxx. |
6. Xxxxx xxxxxxxxx příslušný xxxxx xxxxxx, xx xxxxxxxx xxxxx xxxxxxx zdraví xxxx xxxx zvířat xxxx xxxxxxxxx xxxxxxxxx xxxxxxxxxxx x xxxxxxxxxxxxx xxxxxx xxxxxxxxxx x xxxxxxxxx xxxxxxxxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx xxxx xxxxxxxx xxxxxx látky, xxx obavy zdokumentuje x xxxxxxx s požadavky příslušných xxxxx xxxxxx II xxxx 3 xxxxxxx XX xxxxxxxx Xxxxxxxxxx xxxxxxxxxx x Xxxx (XX) č. 1907/2006 (8) x xxxxxx xx do xxxxx xxxxxx.
7. X xxxxxxx potřeby xx xxxxxxxxx hodnocení xxxxxxxxxxxxx xxxxxxxxx xxxxxxxxx xxxxx xxx xxxxxxxxxx xxxxxxx x xxxxxxxxxx xxx xxxxxxxxxx xxxxxxxxx xxxxxx xxxxx odstavce 3:
|
x) |
předloží xxxxx agentuře xxxxx xx. 37 xxxx. 1 xxxxxxxx (XX) x. 1272/2008, xxxxxxxx xx domnívá, že je xxxxxxx xxxxx z kritérií xxxxxxxxx v čl. 36 odst. 1 xxxxxxxxx xxxxxxxx, ale xxxx xxxxxxxx xxxxxx x xxxxx 3 xxxxxxx XX xxxxxxxxx xxxxxxxx; |
|
b) |
xxxxxxxxxx s agenturou, xxxxx se domnívá, xx xxxxx z kritérií čl. 5 xxxx. 1 xxxx. x) xxxx x) xxxxxxxx (XX) x. 528/2012 xxxx xxxxxxxx xx. 10 xxxx. 1 xxxx. x) xxxxxxxxx xxxxxxxx jsou xxxxxxx, ale nejsou xxxxxxxx řešeny x xxxxxxx XXX nařízení (XX) x. 1907/2006 xxxx v seznamu xxxxxxxx v čl. 59 odst. 1 xxxxxxxxx xxxxxxxx. |
Xxxxxx 7
Stanovisko agentury
1. Xxxxx xxxxxx se použije, xxxxx xxxxx xxxxxxx x xxxxxx xxxxxxxx:
|
a) |
xxxxx hodnotící xxxxxxxxx orgán xxxxxxxxx xxxxxxxxx xxxxxx podle xx. 6 xxxx. 2 a xxxxxxxx xxxxxxxxx xxxxx xxxx xxxxxxx xxxxxxxxxx xxxxx xx. 6 xxxx. 7; |
|
x) |
xxxxx xxxx předložena Xxxxxx xxxxxx xxxxxxxxxxx xxxxxx xxxxx xx. 14 odst. 4 xxxxxxxx (ES) č. 1451/2007, xxx hodnotící xxxxxx xxxxx nepřezkoumal Stálý xxxxx xxx xxxxxxxx xxxxxxxxx xxxxx xx. 15 xxxx. 4 xxxxxxxxx nařízení. |
2. Xx xxxxxxx xxxxxx agentura xxxxxxxxx x xxxxxxxx Xxxxxx xxxxxxxxxx x xxxxxxxxx xxxxxxxxx xxxxx x xxxx přípravku xxxx xxxx xxxxxxxx xx xxxxxxxxx 1, 2, 3, 4, 5 xxxx 6 přílohy X xxxxxxxx (EU) x. 528/2012, xxxxxxxx xxxxxx, x xxxxxxx xx xxxxxx hodnotícího xxxxxxxxxxx xxxxxx.
Xxxxxxxx xxxxxx xxxxxxxx xxxxxxxxxx v jedné x xxxxxx xxxx, xxxxx toho, xx nastane xxxxxxx:
|
x) |
xx xxx xxxxxx po xxxxxxx zprávy; |
|
x) |
xx xxxxx xxxxxxxxx x xxxxxxx XXX. |
Xxxxxxxx xxxxxxxx xxxxxxxxxx Xxxxxx xx 270 xxx xx xxxxxxxx xxxxxxxx.
Xxxxxx 8
Účinné xxxxx, xxxxx se xxxx xxxxxxxx
1. Xxx xxxxxxxx xxxxx xxxxxxxxxx podle xx. 7 xxxx. 2 agentura prověří, xxx xxxxxx xxxxx xxxxxxx některé z kritérií xxxxxxxxx x xx. 10 xxxx. 1 xxxxxxxx (EU) x. 528/2012, x xxxx xxxxxx xxxxx xx xxxx xxxxxxxxxx.
2. Xxxx xxxx xxxxxxx články 66 x 67 xxxxxxxx (XX) x. 528/2012, xxxxx xxx xxxxxxxx xxxxxxxx xxx xxxxxxxxxx Xxxxxx, zveřejní xxxxxxxxx x xxxxxxx xxxxxxx, xxxxx se xxxx xxxxxxxx, během xxxxxxxxx 60 dnů; v xxxx době xxxxx xxxxxxxxxx třetí xxxxxx xxxxxxxxx xxxxxxxxx informace xxxxxx xxxxxxxxx o dostupných xxxxxxxxx. Xxxxxxxx obdržené xxxxxxxxx xxxxxxxx xxxxxxxx x závěrečné xxxx xxxxxxxx xxxxx xxxxxxxxxx.
3. Xxxxx xx xxxxxx xxxxx xxxxxxxxx a splňuje xxxxx x xxxxxxxx stanovených x xx. 10 xxxx. 1 xxxxxxxx (XX) x. 528/2012, xxxx xxx xxxxxxxx xx xxxxx, xxxxx se má xxxxxxxx, x xxxxxxxx přijatém x xxxxxxx s čl. 89 xxxx. 1 xxxxxx xxxxxxxxxxxx uvedeného xxxxxxxx.
Xxxxxx 9
Rozhodnutí Komise
Xx xxxxxxxx xxxxxxxxxx agentury xxxxx xx. 7 xxxx. 2 Xxxxxx bez zbytečného xxxxxxxx připraví xxxxx xxxxxxxxxx xxx přijetí xxxxx xx. 89 xxxx. 1, xxxx xxxxxxxx podle xx. 28 xxxx. 1 nařízení (XX) x. 528/2012.
XXXXXXXX 3
XXXXX XXXXX XXXXXXXX PŘEZKUMU
Článek 10
Xxxxxxxxx xxxx xxxxxxxxx účastníků xx xxxxxxxx dohodě
1. Roli xxxxxxxxx xx možno xx xxxxxxxx xxxxxx xxxx stávajícím xxxxxxxxxx x xxxxxxxxxxxx xxxxxxxxxx xxxxxxx xxxx sdílet xx xxxxxxxxxxx, xx xx potenciální xxxxxxxx xxxxx xxxxxxxxx xx xx xxxxxxx údaje xxxxxxxxxx nebo xxxxxxx xxxxxxxxxx xxxxxxxxxx.
2.&xxxx;&xxxx;&xxxx;Xxxxxxxx pro xxxxx xxxxxx článku xxxxxxxxxxx agentuře společně xxxxxxxxxxx x&xxxx;xxxxxxxxx xxxxxxxx xxxxxxxxxxxxxxx xxxxxxxxx pro xxxxxxxx xxxxxxxxx xxxxxxxxx x xxxxxx 71 xxxxxxxx (EU) x. 528/2012 (xxxx jen „xxxxxxxx“) x&xxxx;xxxxxxxx xxxx xxxxxxxxx xxxxxxx xxxxxxxxx xxxxxxxx x xxxxxxxx.
3.&xxxx;&xxxx;&xxxx;Xx xxxxxxxx xxxxxxxx xxxxxxxxxxx xxxxxxxxx podle odstavce 2 agentura aktualizuje xxxxxxxxx x&xxxx;xxxxxxxxx xxxxxxxx xx xxxxxxxxxx xxxxxxxxx.
4.&xxxx;&xxxx;&xxxx;Xxxxx xxxxxxx xx&xxxx;xxxxx Xxxx, xxxxx převzala xxxx xxxxxxxxx nebo se xxxxxxxxx x xxxxxxxxxxx xxxxx tohoto xxxxxx, xx xxx xxxxx xxxxxx 95 xxxxxxxx (XX) x.&xxxx;528/2012 považována xx xxxxx, xxxxx xxxxxxxxxx xxxxxxxxxxx xxxx xxxxxxxx x xxxxxxxx x xxxxxxxxxxx.
Xxxxxx 11
Odstoupení xxxxxxxxx
1. Xx xx xx xx, xx účastník odstoupil x xxxxxx xx xxxxxxx xxxxxxxxx látky x xxxx přípravku x xxxxxxxx xxxxxxxx, x xxxxxx xxxxxxxxx:
|
x) |
xxxxx informoval xxxxxxxx xxxx xxxxxxxxx xxxxxxxxx xxxxx xxxxxxxxxxxxxxx rejstříku x xxxx xxxxxx xxxxxxxxx; |
|
x) |
xxxxx xxxxxxxxxxx xxxxxx xx lhůtě xxxxxxx x xx. 3 xxxx. 2; |
|
x) |
pokud jeho xxxxxx byla zamítnuta xxxxx čl. 4 xxxx. 1, xx. 4 odst. 4 xxxx xx. 5 odst. 4; |
|
d) |
xxxxx xxxxxxxxxxx xxxxxxxxxx xxxxxxxxx ve xxxxxxx xxxxxxxxx x xx. 6 xxxx. 5; |
|
x) |
xxxxx xxxxx xxxxxxxxxx xxxxxxxx xxxxxxxxxxx xxxxxxxxxxx xxxxxx xxxx xxxxxxxx. |
2. Odstoupení xx považuje xx xxxxxxxxx xxxx, xxxxx x xxxx xxxxxxx xx xxxx, xxx xxxxxxxxx xxxxxxxxx xxxxx xxxxxxxxx xxxxxxxx xxxxxx xxxxxxxxxxx orgánu xxxxx xx. 6 xxxx. 4 xxxxxx xxxxxxxx.
Xxxxxx 12
Důsledky xxxxxxxx xxxxxxxxxx
1. Xxxxx xx o xxxxxxx odstoupení xxxxxxxxxx xxxxxxxxx příslušný orgán, xxx nikoli agentura, xxxxxxxxx ji xxxxxxxxx xxxxxxxxx xxxxx bez xxxxxxxxxx odkladu xxxxxxxxxxxxxxx xxxxxxxxx.
2. Xxxxx xx o xxxxxxx odstoupení xxxxxxxxxxx xxxxxxxx, xxxxxxxxxxx xxxxxxxxx x xxxxxxxxx týkající xx xxxxxxxxxx xxxxxxxxx.
3. Xxxxx x xxxxxxxx xxxxxxxx včas xxxxxxxxxx xxxxxxx účastníci xxxxxxxxxxx xxxxx kombinaci xxxxx x xxxx přípravku x xxxxx byla xxxx xxxxxxxxx pro uvedenou xxxxxxxxx xxxxx převzata, xxxxxxxxx o xxx xxxxxxxx xxxxxxxxxxxxxxx xxxxxxxxx Xxxxxx.
Xxxxxx 13
Xxxx definice xxxxxxxxx xxxxx
1. Xxxxx xxxxxxxxx xxxxxxxxx xxxxxx xxxxx xxxxxxxx vyvodit xxxxxx xxxxxxxx xx xxxxx, xxx xxxx uvedeny x xxxxxxx XX, xxxxxxxxx xxxxxxxxx xxxxx xx xxxxxxxxxx x xxxxxxxx xxxxxxxxxx xxxxxxx xxxxx xxxxxxxx xxxxx. Xxxxxxxxx příslušný xxxxx x xxx informuje xxxxxxxx.
2. Xxxxxxxx v rejstříku aktualizuje xxxxxxxxx týkající xx xxxxxxxx xxxxx.
Xxxxxx 14
Xxxxxxxx role xxxxxxxxx
1. Xxxxxxxx zveřejní otevřenou xxxxx x xxxxxxxx xxxx xxxxxxxxx pro xxxxxxxxx xxxxx a typu xxxxxxxxx, xxxxx xxxxxxx xxxxx x xxxxxx xxxxxxx:
|
x) |
xxxxx xxxxxxx xxxxxxxxx xxxxxxxxxxx xxxxx xxxxxxxxx xxxxx x xxxx přípravku xxxx xxxxxxxxxx xxxxx xxxxxx 11 x xxxxxx xxxx účastníka xxx xxxxx kombinaci xxxxxx předtím převzata; |
|
b) |
na základě xxxx xxxxxxxx xxxxx xxxxxx 13; x xxxxx xxxxxxx xx xxxxx týká xxxxx xx xxxxx, xx xxxxxx xx xxxxxxxx xxxxxxxxx identita x xxxxxxx XX, xxx xxxxxxx xxxx xxxxxxxx xxxxx. |
2. Xx xxxxxxxx měsíců xxx xxx zveřejnění xxxxx xxxxxxxx 1 xxxx xxxxxxxxx xxxxx xxxxxxxxx oznámení pro xxxxxxxxx xxxxx článku 17.
3. Xx xxxxxxxx xxxxxx xx xxxx xxxxxx xxxxxx xxxxxxxx x xxxxxxxx může kterákoli xxxxx oznámit xxxxxxxxx xxxxx a typu přípravku xxxxxxxxx xx xxxxx 2 přílohy II xxxxx xxxxxx 17.
Xxxxxx 15
Xxxxxxxxx xxxxx x xxxx xxxxxxxxx xxxxxxxxx xxx zařazení xx xxxxxxxx přezkumu
Xxxxx xxxxxxxx xxxxxxxxx, xxxxx xxxxx xx xxxxxxx xxxxxxxxxx xxxxxxxx (EU) x. 528/2012 x je xxxxxx xx xxx, xxxxxxx xx xxxxxxxxx xxxxxx xxxxx, xxx xxxx schválena xxx xxxxxxxx xx xxxxxxxx xxxxxxxx pro xxxxx xxx xxxxxxxxx x xxxx zařazena xx xxxxxxx X xxxxxxxxx xxxxxxxx, xxxx látku xxxxxxxx xxxx xx x xx vyrábí, xx uvedená xxxxx xxxxxxxxx xxx zařazení xx xxxxxxxx xxxxxxxx xxx xxxxxxxxx xxx přípravku xx xxxxxxx některého x xxxxxx xxxxxx:
|
x) |
xxxxx uvádějící xxxxxxx xx xxx xx xxxxxxxxx xx xxxxxx xxxx xxxxxxx doporučení vydané Xxxxxx nebo xxxxxxxxxx xxxxxxx jmenovaným v souladu x xxxxxxx 26 xxxxxxxx 98/8/XX nebo xxxxxxx 81 xxxxxxxx (XX) č. 528/2012, xxxxx xx xxxxxxx xxxxxxxxxx opodstatněných xxxxxx xxxxx xxxxxxx xxxxxx xx doporučení k xxxxxxxxxxx, že výrobek byl xxxxx z působnosti směrnice 98/8/XX xxxx xxxxxxxx (XX) x. 528/2012, nebo xx byl xxxxxxxxx xxx xxxxxxxxx xxxxxx x xxxxxxxxx, xxx xxxxx xxxx xxxxxx xxxxx xxxxxxxx, a xxxxx jsou xxxxxxx xxxxxx xx xxxxxxxxxx xxxxxxxx xxxxxxxxxxx x xxxxxxxxxx xxxxxxxx xxxxx xx. 3 xxxx. 3 xxxxxxxx (EU) x. 528/2012 xxxx x xxxxxx, závazných xxxxxxxx xxxxxxxxxxxx Komisí; |
|
x) |
xxxxx xxxxxxxxx odchylky xxx xxxxxxxxx a krmiva xxxxxxxxx x xxxxxx 6 nařízení (XX) x. 1451/2007; |
|
x) |
xxxxxxxx xxxxxxxxx xxxxx xxxxx xxxxxxxx (XX) x. 528/2012 k xxxxxxxxx typu přípravku, xxx tomu xxxx xxxxx směrnice 98/8/ES, v důsledku xxxxx xxxxxxxxxx xxxxxx xxxx xxxxxxxxx x xxxxxxxx xxxxx xxxxxxxxx do programu xxxxxxxx pro původní xxx xxxxxxxxx, xxx xxxxxx pro xxxx. |
Xxxxxx 16
Prohlášení x xxxxx na xxxxxxxx
1. Xxxxxxxxxx x xxxxx oznámit látku, xxxxx xx xxxxxxxxx xxx xxxxxxxx xx xxxxxxxx xxxxxxxx podle xxxxxx 15, předkládá xxxxxxxxxxxxxxx xxxxxxxxx xxxxxxxxx xxxxx, xxx xx xxxxx xxxxxxx kombinaci xxxxx x xxxx xxxxxxxxx, jednomu x xxxxxxxxxxxxx xxxxxxxx:
|
a) |
Komisi xxxxxxxxxx xxxxxxx xxxxxx xx zveřejnění rozhodnutí xxxx xxxxxx uvedených x xx. 15 xxxx. x); |
|
x) |
xxxxxxxx xxxxxxxxxx 30. xxxxx 2015 x xxxxxxxxx xxxxxxxxx x xx. 15 xxxx. x); |
|
c) |
Xxxxxx xxxxxxxxxx 30. xxxxx 2015 v případech xxxxxxxxx x čl. 15 xxxx. x). |
2. Xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxx xxxxxxxxx látky x xxxx xxxxxxxxx. X xxxxxxxxx xxxxxxxxx x xx. 15 písm. x) musí prohlášení xxxxxxxxx xxxxxxxxxxxx xxxxxxxxxx, x xxxx xxxxxxx, xx xxxx splněny xxxxxxx xxxxxxxx x xxx xxxxxxx.
3. Xxxxx bylo xxxxxxxxxx xxxxxxx x xxxxxxx xxxxxxxx x xx. 15 písm. x) xxxx x) x Xxxxxx dospěje po xxxxxxxxxx x xxxxxxxxx xxxxx x závěru, xx xxxxxxxx 6 není xxxxxxxxxx, a případně, xx xxxx xxxxxxx xxxxxxxx xxx xxxxxxxx xxxxxxx x xx. 15 xxxx. x), xxxxxxx x xxx xxxxxxxx.
4. Xxxxx bylo prohlášení xxxxxxx v případě xxxxxxxx x xx. 15 xxxx. x) xxxx xxxxx Komise xxxxxxxxxxx agenturu podle xxxxxxxx 3, zveřejní agentura xxxx xxxxxxxxx xxxxxxxxxxxxxx xxxxxxxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxx látky a typu xxxxxxxxx. Xxx xxxxx xxxxxx nařízení xx xxxxxxxxxx xxxxx xx. 3x xxxx. 3 xxxxxxx xxxxxxxxxxx xxxxxxxx (XX) x. 1451/2007 xxxxxxxx za xxxxxxxxxx xxxxx xxxxxx xxxxxxxx.
5. Xxxxxxxxx xxxxx, xxxxx xx xxxxx xxxxxxx xxxxxxxxx xxxxx x typu xxxxxxxxx, tak může xxxxxx xxxxx xxxxxx 17 xx xxxxx xxxxxx xxx dne zveřejnění xxxxx xxxxxxxx 4.
6. X xxxxxxxxx xxxxxxxxx x xx. 15 xxxx. x) x x) xx xxxxxxxxx látky a typu xxxxxxxxx xxxxxxxx xx xxxxxxxxx účastníkem x xxxx xxxxxxxxx k dalšímu xxxxxxxx, pokud xxxx xxxxxxx tyto xxxxxxxx:
|
x) |
xxxxxxxxx xxxxxx xxxxx xx xxx zařazena xx xxxxxxxx xxxxxxxx; |
|
x) |
xxxxxxxxxxx xxxxxxxxxx xxxxxxxxxxx xxxxxxxxx xxxxx xxx xxxxxxxxxx xxxxxxx xxxxx xxx xxxxxxxx všechny xxxxx, xxxxx xxxx xxxxxxxx xxx hodnocení xxxx přípravku; |
|
x) |
xxxxxxxx, xxxxx xxxxxxxxx xxxxxxxx xxxxxxxxxxx, xxxxx, xx xx xxxxx x xxxxxxx xxxx kombinace xxxxx x xxxx xxxxxxxxx. |
Xxxxxx 17
Xxxxxx xxxxxxxx
1. Xxxxxxxx xxxxx čl. 14 xxxx. 2 x 3 xxxx xx. 16 xxxx. 5 xx xxxxxxxxxxx xxxxxxxx xxxxxxxxxxxxxxx xxxxxxxxx.
2. Xxxxxxxx xxxx xxx xxxxxxxxxx xx xxxxxxx XXXXXX. Xxxx obsahovat xxxxx xxxxxxx x xxxxxxx X.
3. Pokud není x xxxxxxx XX xxx dotyčnou xxxxxxx xxxxx xxxxxx xxxxxxxxx příslušný orgán, xxxxxxxxx oznamovatel xxxxxxxx x xxxxx jím vybraného xxxxxxxxxxx xxxxxx, xxxxx xx xxxxxxxx v souladu x xxxxxxx 81 nařízení (XX) x. 528/2012, a poskytne xxxxxxx xxxxxxxxx xxxxxxxxxxx, že příslušný xxxxx xxxxxxxx s xxx, xx xxxxxxxxxxx xxxxxxx.
4. Xx obdržení oznámení x xxx xxxxxxx xxxxxxxx Xxxxxx x xxxxxxxxxxxx informuje x xxxxxxxxxx xxxxxxxxx xxxxx xxxxxxxx (XX) x. 564/2013. Jestliže xxxxxxxxxxx xxxxxxxx poplatky xx 30 xxx xx xxxxxxx xxxxxxx xxxxxxxxx, xxxxxxxx oznámení xxxxxxx x xxxxxxx x xxx xxxxxxxxxxxx x Komisi.
5. Xx xxxxxxxx xxxxxxxx agentura do 30 dnů xxxxx, xxx oznámení xxxxxxxx xxxxxxxxxx uvedeným x xxxxxxxx 2. Xxxxx xxxxxxxx xxxxx xxxxxxxxxx xxxxxxxxxx, xxxxxxxx agentura xxxxxxxxxxxx lhůtu x xxxxx 30 xxx, xxx xxx xxxxxxxx xxxxxxx nebo xxxxxxx. Xx xxxxxxxx xxxx 30xxxxx lhůty xxxxxxxx xx 30 dnů xxx xxxxxxxx, xx xxxxxxxx vyhovuje požadavkům xxxxxxxx 2, xxxx xxxxxxxx zamítne, a xxx rozhodnutí sdělí xxxxxxxxxxxx x Xxxxxx.
6. V xxxxxxx s xxxxxxx 77 xxxxxxxx (XX) x. 528/2012 proti xxxxxxxxxxx xxxxxxxx xxxxx xxxxxxxx 4 xxxx 5 xxxxx xxxxxxx xxxxxxxxxx.
7. Xxxxx xxxxxxxx xxxxxxxx xxxxxxxxxx xxxxx xxxxxxxx 5:
|
x) |
x xxxxxxx, xx bylo xxxxxxxx předloženo podle xx. 14 xxxx. 2 xxxx 3, agentura neprodleně xxxxxxxxxxx xxxxxxxxx x xxxxxxxxx týkající se xxxxxxxxxx xxxxxxxxx x xxxxxxxx xxxxxxxx látky; |
|
x) |
x xxxxxxx, že oznámení bylo xxxxxxxxxx podle xx. 16 xxxx. 5, xxxxxxxx xxxxxxxxxx xxxxxxxxx Xxxxxx, xx xxxxxxxxxx bylo vyhověno. |
Xxxxxx 18
Zařazení xx xxxxxxxx xxxxxxxx
Xxxxx xx xxxxxxxxx xxxxx x xxxx xxxxxxxxx považována xx xxxxxxxxx x xxxxxxx x xx. 16 xxxx. 6 nebo pokud xxxxxxxx informuje Xxxxxx x dodržení požadavků x xxxxxxx x xx. 17 xxxx. 7 xxxx. x), xxxxxx Xxxxxx kombinaci xxxxx x xxxx přípravku xx xxxxxxxx xxxxxxxx.
Xxxxxx 19
Xxxxxxxxx x xxxxxxx, xxxxx xxxxxx xxxxxx xxxxxxxxxxx x xxxxx programu xxxxxxxx
Pokud xxxxxx xx xxxxx xxxxxxxxx x xx. 16 xxxx. 5 xxxxxxxx xxxxx xxxxxxxx nebo xxxxx xxxx xxxxxxxx xxxxxxx xx xxxxxxxx xxxxxx xxxxxxx x xxxxxxxx xxxxxxxxx agenturou podle xx. 17 odst. 4 nebo 5, xxxxxxxx o tom xxxxxxxxx členské státy xxxxxxxxxxxxxxx rejstříku x xxxxxxxx xxxx informaci xxxxxxxxxxxxx xxxxxx.
Xxxxxx 20
Rozhodnutí Xxxxxx x látkách, xxxxx xxxxxx nadále xxxxxxxxxxx x xxxxx xxxxxxxx xxxxxxxx
Xxxxxx připraví návrh xxxxxxxxxx x xxxxxxxxxxx xxxxx xx. 89 odst. 1 xxxxxxx pododstavce nařízení (XX) č. 528/2012 x xxxxxx xxxxxxxxx:
|
x) |
xxxxx xxxxxxxx informuje Xxxxxx x xxxxxxx xxxxxxxxxx xxxxxxxxx xxxxx xx. 12 xxxx. 3 xxxxxx xxxxxxxx; |
|
x) |
pokud xxxxx xxxxx xxxxxxxx xxxxxxxx xx xxxxxxx stanovených x xx. 14 odst. 2 xxxx 3 xxxxxx xxxxxxxx xxxx xxxxx xxxx xxxxxxxx xxxxxxxxxx x xxxxxxxxx xxxxx xx. 17 xxxx. 4 xxxx 5; |
|
x) |
pokud xxxx xxxxxxxx xxxxxxxxxx xx xxxxx xxxxxxxxx v čl. 14 xxxx. 2 xxxx 3 xxxxxx xxxxxxxx a byly dodrženy xxxxxxxxx xxxxx xx. 17 xxxx. 5 tohoto nařízení, xxx xxxxxxxx xxxxx x xxxxxxxx xxxxxxxx xxxxx xxxx xxxxxxxxx xxxxxxxx x xxxxxxx XX xxxxxx nařízení. |
X xxxxxxx xxxxxxxx x xxxxxx xxxxxxxxxxx xxxx. x) xx xxxxx xxxxxxxxxx x xxxxxxxxxxx xxxxxxxx na xxxxxx xxxxx, na kterou xx xxxxxxxx stávající xxxxxxxx x xxxxxxx XX tohoto xxxxxxxx, avšak xxxxxx xxxxxxxx xxxx jakékoli xxxxxxxxxx o xxxxxxxxx.
XXXXXXXX 4
PŘECHODNÁ XXXXXXXX
Xxxxxx 21
Xxxxxxxxx xxxxxxxx pro xxxxx xxxxxxx x&xxxx;xxxxxx&xxxx;15
1.&xxxx;&xxxx;&xxxx;Xxxxxxx xxxx xxxx xxxxxxxxxx x&xxxx;xxxxxxxxxxx xxxxx xxxxxxxxxxx xxxxxxx nebo praxe xxxxxxxx xx&xxxx;xxx a používání xxxxxxxxxx xxxxxxxxx, xxxxx xxxxxxx xx stávající xxxxxx látky uvedené x čl. 15 xxxx. x) a x), xxxx látku xxxxxxxx xxxx x xx xxxxxx. V xxxxxx xxxxxxxxx:
|
x) |
xxxxx být xxxxxxxx přípravek nadále xxxxxxx xx&xxxx;xxx x&xxxx;xxxxxxx xx&xxxx;24 měsíců po xxxx vstupu tohoto xxxxxxxx x&xxxx;xxxxxxxx; |
|
x) |
xxxxxxxxx zásoby xxxxxxxxxx přípravku xxxxx xxx xxxx xxxxxxxxx xx&xxxx;30 měsíců xx xxx xxxxxx xxxxxx xxxxxxxx v platnost. |
2. Členský stát xxxx pokračovat x&xxxx;xxxxxxxxxxx xxxxx xxxxxxxxxxx xxxxxxx xxxx praxe dodávání xx&xxxx;xxx a používání xxxxxxxxxx xxxxxxxxx, který sestává xx xxxxxxxxx xxxxxx xxxxx xxxxxxx x xx. 15 xxxx. x), xxxx látku xxxxxxxx nebo z xx vzniká. X xxxxxx případech:
|
a) |
nesmí xxx xxxxxxxx xxxxxxxxx xxxxxx xxxxxxx xx&xxxx;xxx x&xxxx;xxxxxxx xx&xxxx;24 xxxxxx po xx z dále xxxxxxxxx xxxxxxxx, xxxxx xxxxxxx později:
|
|
x) |
xxxxxxxxx xxxxxx xxxxxxxxxx přípravku xxxxx xxx dále xxxxxxxxx xx&xxxx;30 xxxxxx xx xx x xxxx xxxxxxxxx událostí, xxxxx nastane xxxxxxx:
|
3.&xxxx;&xxxx;&xxxx;Xxxxxxx xxxx xxxx xxxxxxxxxx x&xxxx;xxxxxxxxxxx svého xxxxxxxxxxx systému nebo xxxxx xxxxxxxx xx&xxxx;xxx x&xxxx;xxxxxxxxx xxxxxxxxxx přípravku, xxxxx xxxxxxx ze xxxxxxxxx xxxxxx látky xxxxxxxxxx xxxxxxxxx xxxxx xx. 16 odst. 4 xxx příslušný xxx výrobku, xxxx xxxxx xxxxxxxx xxxx x xx xxxxxx. X xxxxxx případech:
|
a) |
nesmí xxx xxxxxxxx přípravek xxxxxx xxxxxxx xx&xxxx;xxx x&xxxx;xxxxxxx od dvanácti xxxxxx xx xxxx, kdy xxxxxxxx xxxxxxxx elektronické xxxxxxxxxx xxxxx xxxxxx 19 x |
|
x) |
xxxxxxxxx xxxxxx xxxxxxxxxx xxxxxxxxx xxxxx xxx xxxx využívány xx&xxxx;xxxxxxxx xxxxxx xx xxxx xxxxxxxxx xxxxxxxxxx. |
Xxxxxx 22
Xxxxxxxx xxxxxxx
1. Xxxx xx xxxxxx čl. 55 xxxx. 1 nařízení (XX) x. 528/2012, do osmnácti xxxxxx xx xxxx rozhodnutí x xxxxxxxxxxx xxxxxxxxx xxxxxx xxxxx, xxxxx xxxxxxx stát xxxxxxxx xxxx xxxxxxxxx xxxxxxx xxxxx za xxxxxxxxx x xxxxxx uvedených x xx. 5 xxxx. 2 xxxxxx pododstavci xxxx. x) xxxx x) xxxxxxxx (EU) x. 528/2012, tento xxxxxxx xxxx xxxx xxxxxxxxx Xxxxxx xxxxxxxxxxx žádost x xxxxxxxx od čl. 89 xxxx. 2 xxxxxxx pododstavce xxxxxxxxx xxxxxxxx.
2. Xxxxxxxx xxxxxxx xxxx xxxxxxxx odůvodněnou žádost xxxxxxxx xxxxxxxxxxxxxxx xxxxxxxxx. Xxxxx žádost xxxxxxxx xxxxxxx xxxxxxxxx, xxxxxxxx xxxxxxx xxxx xxxx xxxxxxx xxxxxxxxx xxxxxxxxx xxxxx.
3. Xxxxxxxx zveřejní xxxxxx xxxx případně xxxxxxxxxx xxxxx xxxxxxxxxxxxxx xxxxxxxxxx. Xxxxxxx státy xxxx xxxx xxxxx xxxxx xxxxx připomínky xx xxxxx 60 xxx xx xxxxxxxxxx.
4. Xx zvážení obdržených xxxxxxxxxx xxxx Xxxxxx xxxxxxx odchylku xx xx. 89 xxxx. 2 druhého xxxxxxxxxxx xxxxxxxx (XX) č. 528/2012, xxxxx xxxxxx uvádět xxxxxxxx xxxxxxxxx, xxx xxxxxxxxx x xxxx xxxxx, obsahují xx xxxx x ní xxxxxxxx, xx trh xxxxxxxxxx členského xxxxx x xxxxxxxx xx v daném xxxxxxxx státu v souladu x xxxxxxxxxxxxxx právními předpisy x x xxxxxxxx xxxxxxxx xxxxxxxx 5 x xxxxxxxxx dalších xxxxxxxx xxxxxxxxx Xxxxxx.
5. Xxxxxxx xxxx, xxxxx xx xxxxxxxx xxxxxxxx:
|
x) |
xxxxxxx, xx xxxxx xxxxxxxxx bude xxxxxxx xx xxxxxx xxxxxxx a xxxxxxx xxxx, xxx xxxx plněny xxxxxxxx xxxxxxxx 1; |
|
x) |
xxxxxx xxxxxx xxxxxxxx xx xxxxxxxx xxxxx, xxx xxxxxxxx minimalizaci expozice xxxxxxx, xxxxxx nebo xxxxxxxxx xxxxxxxxx; |
|
x) |
zajistí, xxx xx hledala xxxxxxxxxxxx xxxxxx xxxx xxx xxxx xxxx xxxx xxxxxxxxx xxxxxxxxx xxxxxxxx xxxxxxxxxx xxxxxx o schválení xxxxxx xxxxx v souladu xxxxxxx 7 xxxxxxxx (XX) x. 528/2012. |
XXXXXXXX 5
ZÁVĚREČNÁ XXXXXXXXXX
Xxxxxx 23
Xxxxxxx
Xxxxxxx se nařízení (XX) x. 1451/2007.
Xxxxxx xx xxxxxxx nařízení xx xxxxxxxx za xxxxxx xx toto xxxxxxxx.
Xxxxxx 24
Xxxxx v xxxxxxxx
Xxxx nařízení vstupuje x platnost dvacátým xxxx xx xxxxxxxxx x Xxxxxxx xxxxxxxx Xxxxxxxx unie.
Xxxx xxxxxxxx xx xxxxxxx x celém xxxxxxx x přímo xxxxxxxxxx ve xxxxx xxxxxxxxx xxxxxxx.
X Xxxxxxx xxx 4. xxxxx 2014.
Xx Komisi
xxxxxxxx
José Xxxxxx XXXXXXX
(1) Úř. věst. L 167, 27.6.2012, s. 1.
(2)&xxxx;&xxxx;Xxxxxxxx Xxxxxx (XX) x. 1451/2007 ze xxx 4. xxxxxxxx 2007 o xxxxx xxxxx desetiletého xxxxxxxxxx xxxxxxxx xxxxxxxxx x xx. 16 xxxx. 2 xxxxxxxx Xxxxxxxxxx xxxxxxxxxx x Xxxx 98/8/XX x xxxxxxx xxxxxxxxxx xxxxxxxxx xx xxx (Úř. xxxx. X 325, 11.12.2007, x. 3).
(3) Směrnice Xxxxxxxxxx parlamentu x Rady 98/8/XX xx xxx 16. xxxxx 1998 x xxxxxxx xxxxxxxxxx přípravků xx xxx (Úř. xxxx. L 123, 24.4.1998, x. 1).
(4) Rozsudek Soudního xxxxx (xxxxxxx senátu) xx xxx 1. března 2012 (xxxxxx x xxxxxxxxxx x xxxxxxxxx xxxxxx: Xxxxxxxxxxx Xxxxxxx – Německo) – Xöxx XxxX xxxxx Xxxxx XxxX (xxxxxxx xxxxxxxxxx xxxxxxxxx na xxx – směrnice 98/8/XX – xx. 2 xxxx. 1 xxxx. x) – xxxxx „xxxxxxxx xxxxxxxxx“ – přípravek, xxxxx xxxxxxxxx xxxxxxxxxx xxxxxxxxxx xxxxxxxxx, xxxx je xxxx, xxxxxxxx nebo xxxxxxxxxxx), C-420/10.
(5) Prováděcí xxxxxxxx Komise (XX) x.&xxxx;88/2014 xx xxx 31. ledna 2014, xxxxxx xx stanoví xxxxxx pro xxxxx xxxxxxx X&xxxx;xxxxxxxx Evropského xxxxxxxxxx x&xxxx;Xxxx (XX) x.&xxxx;528/2012 o dodávání biocidních xxxxxxxxx na xxx x&xxxx;xxxxxx používání (Úř. xxxx. X 32, 1.2.2014, x. 3).
(6)&xxxx;&xxxx;Xxxxxxxx Xxxxxxxxxx xxxxxxxxxx x Xxxx (XX) x. 1272/2008 xx xxx 16. xxxxxxxx 2008 x klasifikaci, xxxxxxxxxx a balení xxxxx x xxxxx, x změně x xxxxxxx xxxxxxx 67/548/EHS x 1999/45/XX x x změně xxxxxxxx (XX) x. 1907/2006 (Xx. xxxx. X&xxxx;353, 31.12.2008, x. 1).
(7)&xxxx;&xxxx;Xxxxxxxxx nařízení Xxxxxx (XX) x.&xxxx;564/2013 ze xxx 18.&xxxx;xxxxxx 2013 x&xxxx;xxxxxxxxxx x&xxxx;xxxxxxxx xxxxxxxxx Xxxxxxxx xxxxxxxx xxx xxxxxxxx xxxxx podle xxxxxxxx Xxxxxxxxxx xxxxxxxxxx x&xxxx;Xxxx (XX) x.&xxxx;528/2012 x&xxxx;xxxxxxxx xxxxxxxxxx xxxxxxxxx xx xxx x&xxxx;xxxxxx xxxxxxxxx (Úř. věst. L 167, 19.6.2013, x. 17).
(8)&xxxx;&xxxx;Xxxxxxxx Xxxxxxxxxx parlamentu x Xxxx (XX) x. 1907/2006 xx xxx 18. xxxxxxxx 2006 x registraci, xxxxxxxxx, xxxxxxxxxx a xxxxxxxxx xxxxxxxxxx látek, x zřízení Xxxxxxxx xxxxxxxx xxx xxxxxxxx xxxxx, x xxxxx xxxxxxxx 1999/45/XX x x xxxxxxx nařízení Xxxx (EHS) x.&xxxx;793/93, xxxxxxxx Xxxxxx (ES) x. 1488/94, xxxxxxxx Xxxx 76/769/XXX x xxxxxxx Xxxxxx 91/155/XXX, 93/67/XXX, 93/105/XX x 2000/21/XX (Úř. xxxx. X 396, 30.12.2006, x. 1).
XXXXXXX I
Informace xxxxxxxxxx xxx oznámení xxxxx xxxxxx 17
Xxxxxxxx xxxxx xxxxxx 17 xxxxxxxx xxxx informace:
|
1) |
xxxxx, xx xxxxx xx xxxxxxxxx xxxxxxx xxxxxx xx xxxxxx čl. 3 xxxx. 1 písm. d) xxxxxxxx (XX) č. 528/2012; |
|
2) |
xxxxx x xxxx/xxxxxx přípravku, na xxxxx/x se xxxxxxxx xxxxxxxx; |
|
3) |
xxxxxxxxx o všech studiích, xxxxx xxxx xxxxxx xxx xxxxx žádosti x xxxxxxxxx xx xxxxxxxx xx xxxxxxx X xxxxxxxx (EU) x. 528/2012, xxxxx i očekávané xxxxx xxxxxx xxxxxxxxx; |
|
4) |
informace xxxxxxx x oddílech
|
|
5) |
xxxxx xxxx xxxx oznámení xxxxxxx x xxxxxxx xxxxxxxx x xx. 15 xxxx. x), xxxxx, že látka byla xx xxxx xxxx xxxxxx xxxxx xxxxxxxxxx přípravku xxxxxxxxxxx do příslušného typu xxxxxxxxx v den oznámení xxxx xxxxxxxxxx xxxxxxxxxx xxxx pokynů xxxxxxxxx xx xxxxxxxx xxxxxxx. |
XXXXXXX XX
XXXXXXXXX LÁTKY X XXXX PŘÍPRAVKU ZAŘAZENÉ XX XXXXXXXX XXXXXXXX XXX 4. XXXXX 2014
XXXX 1
Xxxxxxxxx xxxxxx xxxxx x xxxx přípravku xxxxxxxxxxx xx xxx 4. xxxxx 2014, x xxxxxxxx xxxxxxxxxx jiných nanomateriálů xxx xxxx, xxxxx xxxx xxxxxxxx xxxxxxx x xxxxxxxxx 1017 a 1019.
|
Xxxxx xxxxxxx |
Xxxxx látky |
Xxxxxxx stát xxxxxxxxx |
Xxxxx XX |
Xxxxx XXX |
1 |
2 |
3 |
4 |
5 |
6 |
7 |
8 |
9 |
10 |
11 |
12 |
13 |
17 |
18 |
19 |
21 |
22 |
|
1 |
xxxxxxxxxxx |
DE |
200-001-8 |
50-00-0 |
|
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
6 |
5-{[2-(2-xxxxxxxxxxxx)xxxxxx]xxxxxx}-6- xxxxxx-1,3-xxxxxxxxxxx (xxxxxxxxxxxxxxxx/XXX) |
XX |
200-076-7 |
51-03-6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
9 |
xxxxxxxx |
XX |
200-143-0 |
52-51-7 |
|
x |
|
|
|
x |
|
|
x |
|
x |
x |
|
|
|
|
|
x |
|
29 |
xxxxxxxxxxx |
XX |
200-431-6 |
59-50-7 |
x |
x |
x |
|
|
x |
|
|
x |
|
|
|
x |
|
|
|
|
|
|
36 |
xxxxxxx |
XX |
200-578-6 |
64-17-5 |
x |
x |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
37 |
xxxxxxxx xxxxxxxx |
XX |
200-579-1 |
64-18-6 |
|
x |
x |
x |
x |
x |
|
|
|
|
x |
x |
|
|
|
|
|
|
|
40 |
xxxxxx-2-xx |
DE |
200-661-7 |
67-63-0 |
x |
x |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
43 |
xxxxxxxx salicylová |
XX |
200-712-3 |
69-72-7 |
|
x |
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
45 |
xxxxxx-1-xx |
XX |
200-746-9 |
71-23-8 |
x |
x |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
52 |
xxxxxxxxxxx |
X |
200-849-9 |
75-21-8 |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
60 |
kyselina xxxxxxxxx |
XX |
201-069-1 |
77-92-9 |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
69 |
xxxxxxxxx xxxxxxxx/2-xxxxxxxxxxxxxxx xxxxxxxx |
LT |
201-180-5 |
79-14-1 |
|
x |
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
70 |
xxxxxxxx xxxxxxxxxxxx |
XX |
201-186-8 |
79-21-0 |
x |
x |
x |
x |
x |
x |
|
|
|
|
x |
x |
|
|
|
|
|
|
|
71 |
X-(+)-xxxxxx xxxxxxxx |
DE |
201-196-2 |
79-33-4 |
|
x |
x |
x |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
79 |
2-xxxxxxxxxxx-8,9-xxxxxxxxx-1,2,6,6x,12,12x-xxxxxxxxxxxxxxxxx[3,4-x]xxxx[2,3-x]xxxxxxx-6-xx (xxxxxxx) |
UK |
201-501-9 |
83-79-4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
85 |
symklosen |
XX |
201-782-8 |
87-90-1 |
|
x |
x |
x |
x |
|
|
|
|
|
x |
x |
|
|
|
|
|
|
|
92 |
xxxxxxx-2-xx |
ES |
201-993-5 |
90-43-7 |
x |
x |
x |
x |
|
x |
x |
|
x |
x |
|
|
x |
|
|
|
|
|
|
113 |
cinnamaldehyd/3-fenylprop-2-enal (xxxxxxxxxxxxx) |
XX |
203-213-9 |
104-55-2 |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
117 |
xxxxxxxx |
XX |
203-377-1 |
106-24-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
x |
|
|
|
122 |
xxxxxxx |
XX |
203-474-9 |
107-22-2 |
|
x |
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
133 |
xxxx-2,4-xxxxxxx kyselina (xxxxxxxx xxxxxxx) |
XX |
203-768-7 |
110-44-1 |
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
136 |
xxxxxxxx (xxxxxxxxxxxxx) |
XX |
203-856-5 |
111-30-8 |
|
x |
x |
x |
|
x |
|
|
|
|
x |
x |
|
|
|
|
|
|
|
154 |
chlorofen |
X |
204-385-8 |
120-32-1 |
|
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
171 |
2-xxxxxxxxxxx-1-xx |
XX |
204-589-7 |
122-99-6 |
x |
x |
|
x |
|
x |
|
|
|
|
|
|
x |
|
|
|
|
|
|
172 |
xxxxxxxxxxxxxxx-xxxxxxx/1-xxxxxxxxxxxxxxxx-1-xxx-xxxxxxx |
UK |
204-593-9 |
123-03-5 |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
179 |
xxxx xxxxxxxx |
XX |
204-696-9 |
124-38-9 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
180 |
(natrium-kakodylát) – xxxxxxx-xxxxxxxxxxxxxxx |
PT |
204-708-2 |
124-65-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
185 |
xxxxxxxxxxxxxx, xxxxx xxx (sodná xxx xxxxxxxxxxxxxxx – xxxxxxxxx X) – (N-chlor-4-methylbenzen-1-sulfonamid |
XX |
204-854-7 |
127-65-1 |
|
x |
x |
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
187 |
kalium-dimethyldithiokarbamát |
XX |
204-875-1 |
128-03-0 |
|
|
|
|
|
|
|
|
x |
|
x |
x |
|
|
|
|
|
|
|
188 |
xxxxxxx-xxxxxxxxxxxxxxxxxxxxxx |
XX |
204-876-7 |
128-04-1 |
|
|
|
|
|
|
|
|
x |
|
x |
x |
|
|
|
|
|
|
|
195 |
natrium-bifenyl-2-olát |
ES |
205-055-6 |
132-27-4 |
x |
x |
x |
x |
|
x |
x |
|
x |
x |
|
|
x |
|
|
|
|
|
|
198 |
X-[(xxxxxxxxxxxxxx)xxxxxxxx]xxxxxxxx (xxxxxx) |
XX |
205-088-6 |
133-07-3 |
|
|
|
|
|
|
x |
|
x |
|
|
|
|
|
|
|
|
|
|
206 |
xxxxxx |
XX |
205-286-2 |
137-26-8 |
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
210 |
xxxxxx-xxxxxxx |
XX |
205-293-0 |
137-42-8 |
|
|
|
|
|
|
|
|
x |
|
x |
|
|
|
|
|
|
|
|
227 |
2-(xxxxxxx-4-xx)xxxxxxxxxxxx (xxxxxxxxxxxx) |
XX |
205-725-8 |
148-79-8 |
|
|
|
|
|
|
x |
|
x |
x |
|
|
|
|
|
|
|
|
|
235 |
diuron |
XX |
206-354-4 |
330-54-1 |
|
|
|
|
|
|
x |
|
|
x |
|
|
|
|
|
|
|
|
|
239 |
xxxxxxxxxxxxx |
XX |
206-992-3 |
420-04-2 |
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
253 |
xxxxxxxxxx-3,5-xxxxxxxx-1,3,5-xxxxxxxxxx-2-xxxxx (dazomet) |
BE |
208-576-7 |
533-74-4 |
|
|
|
|
|
x |
|
|
|
|
|
x |
|
|
|
|
|
|
|
279 |
X-[(xxxxxxxxxxxxxxxxxx)xxxxxxxx]-X′,X′-xxxxxxxx-X-(4-xxxxxxxxxxx)xxxxxxxxxx (xxxxxxxxxxxx) |
XX |
211-986-9 |
731-27-1 |
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
x |
|
|
283 |
xxxxxxxxx |
XX |
212-950-5 |
886-50-0 |
|
|
|
|
|
|
x |
|
x |
x |
|
|
|
|
|
|
|
|
|
288 |
X-[(xxxxxxxxxxxxxxxxxx)xxxxxxxx]-X-xxxxx-X′,X′-xxxxxxxxxxxxxxxx (xxxxxxxxxxxxx) |
UK |
214-118-7 |
1085-98-9 |
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
x |
|
|
289 |
xxxxxxxxxxxx xxxxx |
XX |
214-183-1 |
1111-67-7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
292 |
[(1,3-dioxo-1,3,4,5,6,7-hexahydro-2H-isoindol-2-yl)methyl]-trans-2,2-dimethyl-3-(2-methylprop-1-en-1-yl)cyklopropan-1-karboxylát (x-xxxxx-xxxxxxxxxxxx) |
XX |
214-619-0 |
1166-46-7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
958 |
xxxxxxxx xxxxxxxx/xxxxxxxxxxx xxxxx/xxxxxx xxxxx |
XX |
215-137-3 |
1305-62-0 |
|
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
959 |
xxxx vápenatý/vápno/pálené xxxxx/xxxxxxxx xxxxx |
XX |
215-138-9 |
1305-78-8 |
|
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
306 |
xxxx měďný |
FR |
215-270-7 |
1317-39-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
315 |
xxxxx-2-xx-xxxxxxx |
XX |
215-661-2 |
1338-23-4 |
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
321 |
xxxxxxxxxxx |
XX |
217-129-5 |
1746-81-2 |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
330 |
N-(3-aminopropyl)-N-dodecylpropan-1,3-diamin (diamin) |
XX |
219-145-8 |
2372-82-9 |
|
x |
x |
x |
|
x |
|
x |
|
|
x |
x |
x |
|
|
|
|
|
|
336 |
X,X′-xxxxxxxx-2,2′-xxxxxxxxxxxxxxxxxxxxxx (XXXXX) |
XX |
219-768-5 |
2527-58-4 |
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
339 |
1,2-xxxxxxxxxxxxxxx-3(2X)-xx (XXX) |
XX |
220-120-9 |
2634-33-5 |
|
x |
|
|
|
x |
|
|
x |
|
x |
x |
x |
|
|
|
|
|
|
341 |
2-xxxxxxxxxxxxxxxxxxxxxxxxxx-3(2X)-xx (XXX) |
XX |
220-239-6 |
2682-20-4 |
|
|
|
|
|
x |
|
|
|
|
x |
x |
x |
|
|
|
|
|
|
346 |
natrium-dichlorisokyanurát xxxxxxxx |
XX |
220-767-7 |
51580-86-0 |
|
x |
x |
x |
x |
|
|
|
|
|
x |
x |
|
|
|
|
|
|
|
345 |
xxxxxxx-xxxxxxxxxxxxxxxxxx |
XX |
220-767-7 |
2893-78-9 |
|
x |
x |
x |
x |
|
|
|
|
|
x |
x |
|
|
|
|
|
|
|
348 |
xxxxx(xxxxxxxxx)xxxxxxxxxxxxxxx-xxxxx-xxxxxx (MES) |
XX |
221-106-5 |
3006-10-8 |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
354 |
triklosan |
XX |
222-182-2 |
3380-34-5 |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
359 |
(xxxxxxxxxxxx)xxxxxxxxxx (xxxxxxx xxxxxxxx xxxxxxxxxxxxxx x xxxxxxxxxxxxxxxx (EGForm)) |
XX |
222-720-6 |
3586-55-8 |
|
x |
|
|
|
x |
|
|
|
|
x |
x |
x |
|
|
|
|
|
|
365 |
xxxxxxx-2-xxxxx-1-xxxx, xxxxx xxx (pyrithion xxxxx) |
XX |
223-296-5 |
3811-73-2 |
|
x |
x |
|
|
x |
x |
|
x |
x |
|
|
x |
|
|
|
|
|
|
368 |
1-(3-chlorallyl)-3,5,7-triaza-1-azoniaadamantan-chlorid (XXXX) |
XX |
223-805-0 |
4080-31-3 |
|
|
|
|
|
x |
|
|
|
|
|
x |
x |
|
|
|
|
|
|
377 |
1,3,5-xxxx(2-xxxxxxxxxxxx)xxxxxxxxx-1,3,5-xxxxxxx (XXX) |
XX |
225-208-0 |
4719-04-4 |
|
|
|
|
|
x |
|
|
|
|
x |
x |
x |
|
|
|
|
|
|
382 |
1,3,4,6-tetrakis(hydroxymethyl)hexahydroimidazo[4,5-d]imidazol-2,5-dion (XXXX) |
ES |
226-408-0 |
5395-50-6 |
|
x |
|
|
|
x |
|
|
|
|
x |
x |
x |
|
|
|
|
|
|
387 |
xxxxxxxxxxxxxxxxx (XXX) |
XX |
227-062-3 |
5625-90-1 |
|
|
|
|
|
x |
|
|
|
|
|
|
x |
|
|
|
|
|
|
392 |
xxxxxxxx-xxxxxxxxxxxx |
XX |
228-652-3 |
6317-18-6 |
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
393 |
1,3-xxx(xxxxxxxxxxxxx)-5,5-xxxxxxxxxxxxxxxxxxxx-2,4-xxxx (DMDMH) |
XX |
229-222-8 |
6440-58-0 |
|
|
|
|
|
x |
|
|
|
|
|
|
x |
|
|
|
|
|
|
397 |
didecyldimethylamonium-chlorid (XXXX) |
XX |
230-525-2 |
7173-51-5 |
x |
x |
x |
x |
|
x |
|
x |
|
x |
x |
x |
|
|
|
|
|
|
|
401 |
stříbro |
XX |
231-131-3 |
7440-22-4 |
|
x |
|
x |
x |
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
403 |
xxx |
FR |
231-159-6 |
7440-50-8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
405 |
xxxx xxxxxxxx |
XX |
231-195-2 |
7446-09-5 |
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
424 |
xxxxxx sodný |
XX |
231-599-9 |
7647-15-6 |
|
x |
|
|
|
|
|
|
|
|
x |
x |
|
|
|
|
|
|
|
432 |
xxxxxxxx xxxxx |
XX |
231-668-3 |
7681-52-9 |
x |
x |
x |
x |
x |
|
|
|
|
|
x |
x |
|
|
|
|
|
|
|
434 |
xxxxxxxxxxxx |
XX |
231-711-6 |
7696-12-0 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
439 |
peroxid xxxxxx |
XX |
231-765-0 |
7722-84-1 |
x |
x |
x |
x |
x |
x |
|
|
|
|
x |
x |
|
|
|
|
|
|
|
444 |
7x-xxxxxxxxxxxx-1X,3X,5X-xxxxxxx[3,4-x]xxxxxx (XXXX) |
XX |
231-810-4 |
7747-35-5 |
|
|
|
|
|
x |
|
|
|
|
|
|
x |
|
|
|
|
|
|
450 |
dusičnan xxxxxxxx |
XX |
231-853-9 |
7761-88-8 |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
453 |
xxxxxxxxxxxxx xxxxx |
XX |
231-892-1 |
7775-27-1 |
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
455 |
xxxxxxxx xxxxxxxx |
XX |
231-908-7 |
7778-54-3 |
|
x |
x |
x |
x |
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
457 |
chlor |
IT |
231-959-5 |
7782-50-5 |
|
x |
|
|
x |
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
458 |
síran xxxxxx |
XX |
231-984-1 |
7783-20-2 |
|
|
|
|
|
|
|
|
|
|
x |
x |
|
|
|
|
|
|
|
473 |
xxxxxxxxxx x pyrethroidy |
XX |
232-319-8 |
8003-34-7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
x |
|
|
|
491 |
oxid xxxxxxxxxx |
XX |
233-162-8 |
10049-04-4 |
|
x |
x |
x |
x |
|
|
|
|
|
x |
x |
|
|
|
|
|
|
|
494 |
2,2-xxxxxx-2-xxxxxxxxxxxx (XXXXX) |
XX |
233-539-7 |
10222-01-2 |
|
x |
|
x |
|
x |
|
|
|
|
x |
x |
x |
|
|
|
|
|
|
501 |
xxxxxxxxxxx |
XX |
234-232-0 |
10605-21-7 |
|
|
|
|
|
|
x |
|
x |
x |
|
|
|
|
|
|
|
|
|
515 |
xxxxxx amonný |
XX |
235-183-8 |
12124-97-9 |
|
|
|
|
|
|
|
|
|
|
x |
x |
|
|
|
|
|
|
|
522 |
zink-1-oxo-1λ5-pyridin-2-thiolát |
XX |
236-671-3 |
13463-41-7 |
|
x |
|
|
|
x |
x |
|
x |
x |
|
|
|
|
|
|
x |
|
|
524 |
xxxxxxxxxxxxxxx-xxxxxxxxxxxxxxxx |
XX |
237-030-0 |
13590-97-1 |
|
|
|
|
|
x |
|
|
|
|
x |
|
|
|
|
|
|
|
|
526 |
xxxxxx-xxxxxxx-2-xxxx |
ES |
237-243-9 |
13707-65-8 |
|
|
|
|
|
x |
|
|
x |
x |
|
|
x |
|
|
|
|
|
|
529 |
xxxxxxxxxxxxxxx |
NL |
237-601-4 |
13863-41-7 |
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
531 |
(xxxxxxxxx)xxxxxxxx |
XX |
238-588-8 |
14548-60-8 |
|
|
|
|
|
x |
|
|
|
|
|
|
x |
|
|
|
|
|
|
534 |
bis(1-hydroxypyridin-2(1H)-thionato-O,S)měďnatý xxxxxxx (xxxxxxxxx xxxx) |
XX |
238-984-0 |
14915-37-8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
541 |
xxxxxxx-4-xxxxx-3-xxxxxxxxxxxxx |
XX |
239-825-8 |
15733-22-9 |
x |
x |
x |
|
|
x |
|
|
x |
|
|
|
x |
|
|
|
|
|
|
550 |
5,5′-xxx(4-xxxxxxxxxx)-1,1′-(xxxxx-1,6-xxxx)xxx(xxxxxxxx)-xxx(x-xxxxxxxx) (XXXX) |
PT |
242-354-0 |
18472-51-0 |
x |
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
554 |
4-[(dijodmethyl)sulfonyl]-1-methylbenzen |
UK |
243-468-3 |
20018-09-1 |
|
|
|
|
|
x |
x |
|
x |
x |
|
|
|
|
|
|
|
|
|
559 |
[(benzothiazol-2-yl)sulfanyl]methyl-thiokyanát (XXXXX) |
X |
244-445-0 |
21564-17-0 |
|
|
|
|
|
|
|
|
x |
|
|
x |
|
|
|
|
|
|
|
562 |
[2-xxxxxx-4-xxx-3-(xxxx-2-xx-1-xx)xxxxxxxxx-2-xx-1-xx]-2,2-xxxxxxxx-3-(2-xxxxxxxxxx-1-xx-1-xx)xxxxxxxxxxx-1-xxxxxxxxxx (xxxxxxxxxxx) |
XX |
245-387-9 |
23031-36-9 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
563 |
xxxxxx-(X,X)-xxxx-2,4-xxxxxxx (xxxxxx xxxxxxxx) |
XX |
246-376-1 |
24634-61-5 |
|
|
|
|
|
x |
|
x |
|
|
|
|
|
|
|
|
|
|
|
566 |
α, α′,α′′-xxxxxxxxxxxxxxxxxx-1,3,5-xxxxxxx-1,3,5-xxxxxxxxxx (XXX) |
XX |
246-764-0 |
25254-50-6 |
|
x |
|
|
|
x |
|
|
|
|
x |
|
x |
|
|
|
|
|
|
571 |
2-xxxxxxxxxxxxxxxxxxxxxxxxx-3-xx (XXX) |
XX |
247-761-7 |
26530-20-1 |
|
|
|
|
|
x |
x |
|
x |
x |
x |
|
x |
|
|
|
|
|
|
577 |
dimethyl(oktadecyl)[3-(trimethoxysilyl)propyl]amonium-chlorid |
XX |
248-595-8 |
27668-52-6 |
|
x |
|
|
|
|
x |
|
x |
|
|
|
|
|
|
|
|
|
|
578 |
X2-xxxx-xxxxx-X4-xxxxxxxxxxx-6-(xxxxxxxxxxxxxx)-1,3,5-xxxxxxx-2,4-xxxxxx (xxxxxxxx) |
XX |
248-872-3 |
28159-98-0 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
588 |
xxxxxxxxx-5,5-xxxxxxxxxxxxxxxxxxxx-2,4-xxxx (BCDMH/bromchlordimethylhydantoin) |
NL |
251-171-5 |
32718-18-6 |
|
x |
|
|
|
|
|
|
|
|
x |
x |
|
|
|
|
|
|
|
590 |
3-(4-xxxxxxxxxxxxxx)-1,1-xxxxxxxxxxxxxxxx/xxxxxxxxxxx |
XX |
251-835-4 |
34123-59-6 |
|
|
|
|
|
|
x |
|
|
x |
|
|
|
|
|
|
|
|
|
597 |
1-[2-(allyloxy)-2-(2,4-dichlorfenyl)ethyl]imidazol (xxxxxxxx) |
XX |
252-615-0 |
35554-44-0 |
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
599 |
X-[(6-xxxxx-2-xxxxxxxxxx[4,5-x]xxxxxxx-3(2X)-xx)xxxxxx]-X,X-xxxxxxxx-xxxxxxxxxxxxx (xxxxxxxxxxx) |
XX |
252-626-0 |
35575-96-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
600 |
2-xxxx-2-(xxxxxxxxxx)xxxxxxxxxxxxxx (XXXXX) |
XX |
252-681-0 |
35691-65-7 |
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
961 |
oxid xxxxxxxx-xxxxxxxxx/xxxxxxxxxxx xxxxx |
XX |
253-425-0 |
37247-91-9 |
|
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
962 |
xxxxxxxx xxxxxxxx-xxxxxxxxx/xxxxxxxxxxx dolomitické xxxxx |
XX |
254-454-1 |
39445-23-3 |
|
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
606 |
[(3-xxxxxxxxxxx)xxxxxxxxxx]-2,2-xxxxxxxx-3-(2-xxxxxxxxxx-1-xx-1-xx)xxxxxxxxxxx-1-xxxxxxxxxx (xxxxxxxxxxx) |
XX |
254-484-5 |
39515-40-7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
608 |
xxxxxxxx(xxxxxxxxxx)[3-(xxxxxxxxxxxxxxx)xxxxxx]xxxxxxx-xxxxxxx |
XX |
255-451-8 |
41591-87-1 |
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
609 |
xxx- x xxxxx-x-xxxxxxx-3,8-xxxx (xxxx) (xxxxxxxxxx) |
XX |
255-953-7 |
42822-86-6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
614 |
(RS)-α-kyano-3-fenoxybenzyl-(1RS)-cis,trans-3-(2,2-dichlorvinyl)-2,2-dimethylcyklopropanekarboxylát (xxxxxxxxxxxx) |
XX |
257-842-9 |
52315-07-8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
615 |
3-xxxxxxxxxxxx(1XX,3XX;1XX,3XX)-3-(2,2-xxxxxxxxxxxx)-2,2-xxxxxxxxxxxxxxxxxxxxxxxxxxxxx (permethrin) |
XX |
258-067-9 |
52645-53-1 |
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
x |
|
|
|
|
618 |
[1-ethynyl-2-methylpent-2-en-1-yl]-2,2-dimethyl-3-(2-methylprop-1-en-1-yl)cyklopropan-1-karboxylát (xxxxxxxxxx) |
XX |
259-154-4 |
54406-48-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
619 |
3-xxxxxxx-2-xx-1-xx-X-xxxxxxxxxxxxx (XXXX) |
XX |
259-627-5 |
55406-53-6 |
|
|
|
|
|
|
x |
|
x |
x |
|
|
x |
|
|
|
|
|
|
620 |
xxxxxxxx(xxxxxxxxxxxxx)xxxxxxxxx-xxxxxx (2:1) (XXXX) |
MT |
259-709-0 |
55566-30-8 |
|
x |
|
|
|
x |
|
|
|
|
x |
x |
|
|
|
|
|
|
|
628 |
(±)-1-{[2-(2,4-dichlorfenyl)-4-propyl- 1,3-xxxxxxxx-2-xx]xxxxxx}-1X-1,2,4-xxxxxxx (xxxxxxxxxxxx) |
XX |
262-104-4 |
60207-90-1 |
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
635 |
xxxxxxxxxxxxxxxxxxxxxxxxxxxxx kokosového xxxxx (XXXXX/XXXX) |
XX |
263-038-9 |
61789-18-2 |
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
648 |
4,5-xxxxxxx-2-xxxxxxxxxxxxxxx-3(2X)-xx (4,5-dichlor- 2-xxxxx-2X-xxxxxxxxxx-3-xx (XXXXX)) |
X |
264-843-8 |
64359-81-5 |
|
|
|
|
|
|
x |
|
x |
x |
x |
|
|
|
|
|
|
|
|
649 |
1-(2-xxxxxxxxxxx)-3-[(xxxxxxxxxxxxxxx)xxxxx]xxxxxxxx (xxxxxxxxxxx) |
XX |
264-980-3 |
64628-44-0 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
656 |
bis(5-methyloxazolidin-3-yl)methan (xxxxxxxxxx/XXX) |
XX |
266-235-8 |
66204-44-2 |
|
x |
|
|
|
x |
|
|
|
|
x |
x |
x |
|
|
|
|
|
|
657 |
6-(xxxxxxxxxxxxxxxx)-1,3,5-xxxxxxx-2,4-xxxxxx (xxxxxxxxx) |
XX |
266-257-8 |
66215-27-8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
666 |
[(3-xxxxxx-4-xxxxxxxxxx)xxxxxxxxxx]-3-(2,2-xxxxxxxxxxxx)-2,2-xxxxxxxxxxxxxxxxxxx-1-xxxxxxxxxx (xxxxxxxxxx) |
XX |
269-855-7 |
68359-37-5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
667 |
xxxxx(X12-18)xxxxxxxxxxxxxxxxxxxxxxxxxxxxx (XXXXX (X12-18)) |
IT |
269-919-4 |
68391-01-5 |
x |
x |
x |
x |
|
|
|
|
|
x |
x |
x |
|
|
|
|
|
x |
|
671 |
xxxxx(X12-16)xxxxxxxxxxxxxxxxxxxxxxxxxxxxx (XXXXX/XXX (X12-X16)) |
XX |
270-325-2 |
68424-85-1 |
x |
x |
x |
x |
|
|
|
|
|
x |
x |
x |
|
|
|
|
|
x |
|
673 |
xxxxxxxxxxxxxxxxxxxxxx-xxxxxxx (XXXX) (X8-10) |
XX |
270-331-5 |
68424-95-3 |
x |
x |
x |
x |
|
x |
|
|
|
x |
x |
x |
|
|
|
|
|
|
|
690 |
xxxxx(X12-X18)xxxxxx(xxxxxxxx)xxxxxxxx xxxx 1,1-xxxxx-1λ-1,2-xxxxxxxxxxxxxxx-3(2X)-xxx (ADBAS) |
XX |
273-545-7 |
68989-01-5 |
|
x |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
691 |
xxxxxxx-X-(xxxxxxxxxxxxx)xxxxxxxx |
AT |
274-357-8 |
70161-44-3 |
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
692 |
xxxxx(X10-X16)xxxxxxxxxxxxxxxxx |
XX |
274-687-2 |
70592-80-2 |
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
693 |
xxx(xxxxxxxxxxx)-xxx(xxxxx) xxxxxxxxxxxxx |
XX |
274-778-7 |
70693-62-8 |
|
x |
x |
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
701 |
xxxxxxxxx-xxxxxxxxxxxxxxxx xxxxxxxxxx (XXXX) |
XX |
279-013-0 |
84665-66-7 |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1015 |
margosa, Xxxxxxxxxxx xxxxxx, xxxxxxx |
XX |
283-644-7 |
84696-25-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
724 |
xxxxx(X12-X14)xxxxxxxxxxxxxxxxxxxxxxxxxxxxx (XXXXX (X12-X14)) |
XX |
287-089-1 |
85409-22-9 |
x |
x |
x |
x |
|
|
|
|
|
x |
x |
x |
|
|
|
|
|
x |
|
725 |
alkyl(C12-C14)ethylbenzylammoniumchlorid (XXXXXX (X12-X14)) |
XX |
287-090-7 |
85409-23-0 |
x |
x |
x |
x |
|
|
|
|
|
x |
x |
x |
|
|
|
|
|
x |
|
731 |
xxxxxxxxx xxxxxxxxxxxx, Xxxxxxxxxxxxx xxxxxxxxxxxxxxxx, xxxxxxx |
ES |
289-699-3 |
89997-63-7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
744 |
xxxxxxxxx zvrhlá, Xxxxxxxxx hybrida, výtažek/levandulový xxxx |
XX |
294-470-6 |
91722-69-9 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
776 |
1-[3,5-xxxxxxx-4-(1,1,2,2-xxxxxxxxxxxxxxxx)xxxxx]-3-(2,6-xxxxxxxxxxxxxx)xxxxxxxx (xxxxxxxxxxxx) |
PT |
401-400-1 |
86479-06-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
779 |
reakční produkty xxxxxxxxx kyseliny a X-xxxxx(X12-X14)xxxxxx-1,2-xxxxxxx (xxxxxxxxxxxxx) |
DE |
403-950-8 |
164907-72-6 |
|
x |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
785 |
6-xxxxxxxxxxxxxxxxxxxxxxx xxxxxxxx (XXX) |
XX |
410-850-8 |
128275-31-0 |
x |
x |
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
791 |
2-xxxxx-1,2-xxxxxxxxxxxx-3(2X)-xx (XXXX) |
XX |
420-590-7 |
4299-07-4 |
|
|
|
|
|
x |
x |
|
x |
x |
|
|
x |
|
|
|
|
|
|
792 |
xxxxxxx xxxxxxxxxxxxxxxxxxx (XXXX) |
XX |
420-970-2 |
92047-76-2 |
x |
x |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
811 |
xxxxxxxxxxxxxxxxxxx xxxxxxxx-xxxxx-xxxxxxxxxxx |
XX |
422-570-3 |
265647-11-8 |
x |
x |
|
x |
|
|
x |
|
x |
|
|
|
|
|
|
|
|
|
|
794 |
sek-butyl-2,2-(2-hydroxyethyl)piperidin-1-karboxylát (xxxxxxxx) |
XX |
423-210-8 |
119515-38-7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
797 |
1-((Z)-3-chlorallyl)-3,5,7-triaza-1-azoniaadamantanchlorid (xxx-XXXX) |
XX |
426-020-3 |
51229-78-8 |
|
|
|
|
|
x |
|
|
|
|
|
|
x |
|
|
|
|
|
|
800 |
{[2,5-xxxxx-3-(xxxx-2-xx-1-xx)xxxxxxxxxxxx-1-xx]xxxxxx}-2,2-xxxxxxxx-3- (2-methylprop-1-en-1-yl)cyklopropan- 1-xxxxxxxxxx (xxxx xxxxxxxxxxxxx) (xxxxxxxxxxx) |
UK |
428-790-6 |
72963-72-5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
790 |
5-chlor-2-(4-chlorfenoxy)fenol (XXXX) |
XX |
429-290-0 |
3380-30-1 |
x |
x |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
807 |
(X)-1-[(2-xxxxxxxxxxxx-5-xx)xxxxxx]-3-xxxxxx-2-xxxxxxxxxxxxx (chlothianidin) |
XX |
433-460-1 |
210880-92-5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
952 |
Bacillus xxxxxxxxxx 2362, xxxx ABTS-1743 |
XX |
xxxxxxxxxxxxxxx |
143447-72-7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
955 |
Xxxxxxxx xxxxxxxxxxxxx xxxxx. xxxxxxxxxxx, xxxx XX3X |
XX |
mikroorganismus |
xxxx relevantní |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
957 |
Xxxxxxxx xxxxxxxx |
XX |
xxxxxxxxxxxxxxx |
xxxx xxxxxxxxxx |
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
928 |
5-chlor-2-methylisothiazol-3(2H)-on (Xxxxxx 247-500-7) x 2-xxxxxxxxxxxxxxxx-3(2X)-xx (Xxxxxx 220-239-6), směs (3:1) (xxxx XXXX/XXX) |
XX |
směs |
55965-84-9 |
|
x |
|
x |
|
x |
|
|
|
|
x |
x |
x |
|
|
|
|
|
|
939 |
aktivní xxxxx (xxxxxxxx reakcí xxxxxxxx xxxxxxx a xxxxxxxxx xxxxxxx xx xxxx) |
XX |
xxxx |
xxxx xxxxxxxxxx |
|
x |
x |
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
813 |
xxxxxxxxxxxxxx kyselina |
FR |
není xxxxxxxxxx |
33734-57-5 |
|
x |
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1014 |
xxxxxxxx xxxxxx |
XX |
xxxx xxxxxxxxxx |
xxxx xxxxxxxxxx |
|
x |
|
x |
x |
|
x |
|
x |
|
|
|
|
|
|
|
|
|
|
849 |
3-xxxxxxxxxxxx-(1X,3XX)-2,2-xxxxxxxx-3-(2-xxxxxxxxxx-1-xx-1-xx)xxxxxxxxxxx-1-xxxxxxxxxx (d-fenothrin) |
IE |
xxxx relevantní |
188023-86-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
931 |
alkyltrimethylendiaminy, X-X12-14(xx sudým číslem), xxxxxxxx xxxxxx s xxxxxxxxxxxx xxxxxxxxx (Xxxxxxxx 20) |
XX |
xxxx xxxxxxxxxx |
139734-65-9 |
|
x |
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
152 |
produkty xxxxxx 5,5-xxxxxxxxxxxxxxxxxx, 5-xxxxx-5-xxxxxxxxxxxxxxxx x xxxxxx x xxxxxxx (XXXXX) |
XX |
xxxx k dispozici |
xxxx k dispozici |
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
459 |
reakční xxxx oxidu titaničitého x xxxxxxxx xxxxxxxxxx |
XX |
xxxx x xxxxxxxxx |
xxxx k dispozici |
x |
x |
|
|
|
x |
x |
|
x |
x |
x |
|
|
|
|
|
|
|
|
777 |
xxxxxxx produkty 5,5-xxxxxxxxxxxxxxxxxx, 5-ethyl-5-methylhydantoinu s chlorem (XXXXX) |
XX |
xxxx x xxxxxxxxx |
xxxx k dispozici |
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
810 |
fosforečnanové xxxx x xxxxxxx xxxxxxx |
XX |
xxxx x xxxxxxxxx |
308069-39-8 |
|
x |
|
|
|
|
x |
|
x |
|
|
|
|
|
|
|
|
|
|
824 |
xxxxxxxx-xxxxxxxxx zeolit |
XX |
xxxx x xxxxxxxxx |
130328-20-0 |
|
x |
|
x |
x |
|
x |
|
x |
|
|
|
|
|
|
|
|
|
|
1013 |
xxxxxxxx-xxxxxxx xxxxxx |
XX |
není x xxxxxxxxx |
130328-19-7 |
|
x |
|
x |
x |
|
x |
|
x |
|
|
|
|
|
|
|
|
|
|
1017 |
xxxxxxx xxxxxxxxxxx xx xxxxx xxxxxxxxxx (xxxx xxxxxxxxxxxx xx xxxxx stabilního agregátu x xxxxxxxxxx xxxxxxxxx xx xxxxxxxxxx) |
XX |
není x xxxxxxxxx |
není x xxxxxxxxx |
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
1019 |
xxxx křemičitý (jako xxxxxxxxxxxx xxxxxxx agregáty x xxxxxxxxxx) |
XX |
xxxx k dispozici |
68909-20-6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
831 |
xxxxxxxxx |
XX |
xxxxxxxxx xx xxxxxxx rostlin |
61790-53-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
854 |
(XX)-3-xxxx-2-xxxxx-4-xxxxxxxxxxxx-2-xxxx-(1X,3X;1X,3X)-2,2-xxxxxxx-3-(2-xxxxxxxxx-1-xxxx)-xxxxxxxxxxxxxxxxxxxxx (směs 4 xxxxxxx 1R xxxxx, 1X: 1X xxxxx, 1X: 1R xxx, 1R: 1R xxx, 1S 4:4:1:1) (x-xxxxxxxxx) |
XX |
xxxxxxxxx xx xxxxxxx xxxxxxx |
231937-89-6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
855 |
(XX)-3-xxxxx-2-xxxxxx-4-xxxxxxxxxxxx-2-xx-1-xx-(1X,3X)-2,2-xxxxxxxx-3-(2-xxxxxxxxxx-1-xx-1-xx)xxxxxxxxxxx-1-xxxxxxxxxx (xxxx 2 xxxxxxxxxxxxx) (xxxxxxxxxx) |
XX |
xxxxxxxxx xx xxxxxxx xxxxxxx |
260359-57-7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
848 |
X-[(6-xxxxx-3-xxxxxxx)xxxxxx]-X′-xxxx-X-xxxxxxxxxxxxxxxxxxx (xxxxxxxxxxx) |
BE |
xxxxxxxxx xx ochranu rostlin |
160430-64-8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
835 |
esfenvalerát/(S)-(3-fenoxyfenyl)kyanmethyl-(S)-2-(4-chlorfenyl)-3-methylbutanoát (xxxxxxxxxxxx) |
XX |
xxxxxxxxx na xxxxxxx xxxxxxx |
66230-04-4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
836 |
[(3-xxxxxxxxxxxx)xxxxxxxxxx]-3-(2,2-xxxxxxxxxxxx)-2,2-xxxxxxxxxxxxxxxxxxx-1-xxxxxxxxxx (α-xxxxxxxxxxxx) |
XX |
xxxxxxxxx xx xxxxxxx xxxxxxx |
67375-30-8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
843 |
4-xxxx-2-(4-xxxxxxxxxx)-1-(xxxxxxxxxxxx)-5-(xxxxxxxxxxxxxx)xxxxxx-3-xxxxxxxxxxx (xxxxxxxxxxxx) |
XX |
xxxxxxxxx xx xxxxxxx xxxxxxx |
122453-73-0 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
859 |
polymer X-xxxxxxxxxxxxxxxxx(XXXXXX 204-697-4) s (xxxxxxxxxxx)xxxxxxxx (EINECS 203-439-8)/xxxxxxxxx xxxxxxxxx xxxxxxx amonný (XX Polymer) |
XX |
xxxxxxx |
25988-97-0 |
|
x |
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
863 |
poly(biguanid-1,5-diylhexan-1,6-diyl) (PHMB) |
XX |
polymer |
27083-27-8/32289-58-0 |
x |
x |
x |
x |
x |
x |
|
|
x |
|
x |
|
|
|
|
|
|
|
|
868 |
poly(biguanid-1,5-diylhexan-1,6-diyl-hydrochlorid) |
XX |
polymer |
91403-50-8 |
x |
x |
x |
x |
|
|
|
|
x |
|
x |
|
|
|
|
|
|
|
|
869 |
α-[2-(didecylmethylamonio)ethyl]-ω-[hydroxypoly(oxyethylen)-propionát] (Xxxxxx 26) |
XX |
polymer |
94667-33-1 |
|
x |
|
x |
|
|
|
x |
|
x |
|
|
|
|
|
|
|
|
|
872 |
X-xxxxxxx-X-xxxxxxxxxxxxxxxxxxxx-xxxxx/ α, α ′-(xxxxxxxxxxxxx)xxx[ω-xxxxxxxxx(xxxxxxxxxx)]-xxx xx (xxxxxxxxxxx xxxxxx) |
XX |
xxxxxxx |
214710-34-6 |
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
ČÁST 2
Xxxxxxxxx xxxxxx látky x xxxx přípravku xxxxxxxxxxxxx xx xxx 4. xxxxx 2014
Tato xxxx xxxx přílohy xxxxxxxx
|
— |
kombinace xxxxx a typu xxxxxxxxx xxxxxxx x xxxxxxx xxxx, xxxxxx xxxxxxxxxx xxxxxxxxx, |
|
— |
xxxxxxxx xxxxxxxxx všech xxxxxxxxx xxxxx x xxxx xxxxxxxxx xxxxxxxxx x xxxxxxx x xxxxx 1, xxxxx xxxx, které xxxx xxxxxxx x xxxxxxx, x |
|
— |
xxxxxxxx xxxxxxxxx xxxxx xxxxxxxxx xxxxxxxx xxxxx x xxxx xxxxxxxxx xxxxxxxxxxx xx 4. xxxxx 2014, x xxxxxxxx xxxx, které xxxx výslovně schváleny. |
Kombinace xxxxx x xxxx přípravku x nanomateriály zařazené xx této xxxxx xxxxx xxxxxxxxx rozhodnutí x xxxxxxxxxxx xxxxx xxxxxx 20, jestliže xxxxx xxxxx xxxxxx xxxxxxxx xx xxxxxxxx xxxxxx xx xxxxxx xxxxxx xxxxxxxx x xxxxxxxx podle xx. 14 xxxx. 3 xxxx xxxxx xx takové xxxxxxxx xxxxxxxxx xxxxx xx. 17 xxxx. 4 xxxx 5.
|
Xxxxx položky |
Xxxxx xxxxx |
Xxxxxxx xxxx xxxxxxxxx |
Číslo XX |
Číslo XXX |
1 |
2 |
3 |
4 |
5 |
6 |
7 |
8 |
9 |
10 |
11 |
12 |
13 |
17 |
18 |
19 |
21 |
22 |
|
1021 |
1,3-xxxxxxx-5,5-xxxxxxxxxxxxxxxxx (xxxx definovaný xxxxx xxxxxxx 152) |
XX |
204-258-7 |
118-52-5 |
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
166 |
xxxxxx(xxxxxxxxx)xxxxxxxxxxxxxxx-xxxxxxx (xxx položka 948) |
|
204-526-3 |
122-18-9 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
167 |
benzyl(dimethyl)oktadecylamonium-chlorid (xxx xxxxxxx 948) |
|
204-527-9 |
122-19-0 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
213 |
benzyl(dodecyl)dimethylamonium-chlorid (xxx xxxxxxx 948) |
|
205-351-5 |
139-07-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
214 |
xxxxxx(xxxxxxxx)xxxxxxxxxxxxxxxxx-xxxxxxx (xxx xxxxxxx 948) |
|
205-352-0 |
139-08-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
227 |
2-(thiazol-4-yl)benzimidazol (xxxxxxxxxxxx) |
XX |
205-725-8 |
148-79-8 |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
331 |
xxxxxxxxxxxxxxxxxxxxxx-xxxxxx (viz xxxxxxx 949) |
|
219-234-1 |
2390-68-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
384 |
xxxxxxxx(xxxxxxx)xxxxxxx-xxxxxxx (xxx položka 949) |
|
226-901-0 |
5538-94-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
399 |
xxxxxx(xxxxxxx)xxxxxxxxxxxxxxx-xxxxxx (xxx položka 948) |
|
230-698-4 |
7281-04-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
401 |
xxxxxxx |
XX |
231-131-3 |
7440-22-4 |
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
418 |
xxxx křemičitý amorfní |
XX |
231-545-4 |
7631-86-9 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
449 |
xxxxx xxxxxxx |
XX |
231-847-6 |
7758-98-7 |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1016 |
xxxxxxx stříbrný |
XX |
232-033-3 |
7783-90-6 |
x |
x |
|
|
|
x |
x |
|
x |
x |
x |
|
|
|
|
|
|
|
|
554 |
4-[(xxxxxxxxxxx)xxxxxxxx]-1-xxxxxxxxxxxx |
XX |
243-468-3 |
20018-09-1 |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
587 |
decyl(dimethyl)oktylamonium-chlorid (xxx xxxxxxx 949) |
|
251-035-5 |
32426-11-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
601 |
xxxxxxxxxxxxxx(xxxxxxx-9-xx-1-xx)xxxxxxx-xxxxxxx (xxx xxxxxxx 948) |
|
253-363-4 |
37139-99-4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
615 |
3-xxxxxxxxxxxx(1XX,3XX;1XX,3XX)-3-(2,2-xxxxxxxxxxxx)-2,2-xxxxxxxxxxxxxxxxxxxxxxxxxxxxx (permethrin) |
XX |
258-067-9 |
52645-53-1 |
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
637 |
xxxxx(xxxxxx)xxxxxxxxxxxxxxx-xxxxxxxx (xxxxx xxxxxxx xx xxxxxxxx xxxxxxx kokosového xxxxx) (xxx položka 948) |
|
263-080-8 |
61789-71-7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
638 |
xxxxxxx(xxxxxxxx)xxxxxxx-xxxxxxxx (xxxxx odvozen xx xxxxxxxx xxxxxxx xxxxxxxxxx xxxxx) (viz xxxxxxx 949) |
|
263-087-6 |
61789-77-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
639 |
dialkyl(dimethyl)amonium-chloridy (xxxxx xxxxxxx xx hydrogenovaných xxxxxxxx kyselin loje) (xxx položka 949) |
|
263-090-2 |
61789-80-8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
647 |
alkyl(C8-C18)benzyl(dimethyl)amonium-chloridy (xxx xxxxxxx 948) |
|
264-151-6 |
63449-41-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
668 |
dialkyl(C6-C12)dimethylamonium-chloridy (xxx xxxxxxx 949) |
|
269-925-7 |
68391-06-0 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
670 |
xxxxx(X8-X16)xxxxxx(xxxxxxxx)xxxxxxx-xxxxxxxx (xxx xxxxxxx 948) |
|
270-324-7 |
68424-84-0 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
689 |
xxxxx(X10-X16)xxxxxx(xxxxxxxx)xxxxxxx-xxxxxxxx (xxx položka 948) |
|
273-544-1 |
68989-00-4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
692 |
xxxxx(X10-X16)xxxxxxxxxxxxxxxxx |
PT |
274-687-2 |
70592-80-2 |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
697 |
dialkyl(C8-C18)dimetylamonium-chloridy (xxx xxxxxxx 949) |
|
277-453-8 |
73398-64-8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1000 |
xxxxxxxxxx-xxx(xxxxxxxxxxxxxxxxx)xxxxxxxx xxxxxxxxxx |
XX |
279-013-0 |
14915-85-4 |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
998 |
xxxxxxx xxxxxxx xxxx xxx z xxxxx xxxxxxxx Xxxxxxxxxxx indica xxxxxxxxxxx xxxxx x xxxx xxxxxxxxxx organickými xxxxxxxxxxxx |
XX |
283-644-7 |
84696-25-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
741 |
xxxxx(X8-X18)xxxxxx(xxxxxxxx)xxxxxxx-xxxxxxx (xxx xxxxxxx 948) |
|
293-522-5 |
91080-29-4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1020 |
1,3-xxxxxxx-5-xxxxx-5-xxxxxxxxxxxxxxxxxx-2,4-xxxx (xxxx xxxxxxxxxx xxxxx xxxxxxx 777) |
XX |
401-570-7 |
89415-87-2 |
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
778 |
1-(4-chlorfenyl)-4,4-dimethyl-3-[(1H-1,2,4-triazol-1-yl)methyl]pentan-3-ol (xxxxxxxxxxx) |
XX |
403-640-2 |
107534-96-3 |
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
805 |
xxxxxxx produkt dimethyl-adipátu, xxxxxxxx-xxxxxxxxx a xxxxxxxx-xxxxxxxxx x xxxxxxxxx vodíku (xxxxxxxx) |
XX |
432-790-1 |
xxxx relevantní |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
923 |
xxxxx(xxxxxx)xxxxxxxxxxxxxxx-xxxxxxx/xxxxxxxxxxxx-xxxxxxx (xxx xxxxxxx 948) |
|
xxxx |
8001-54-5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
949 |
(xxxxxxx)xxxxxxxxxxxxxxx-xxxxxxxx, -xxxxxxx xxxx -xxxxxx-xxxxxxx) (alkyly (X6-X18) xxxxxxxx x xxxxxxxxxx, xxxxxxxx xx xxxxxxxx kyselin loje, xxxxxxxxxx xxxxx a xxxxxxxx xxxxx) (XXXX) |
XX |
xxxx xxxxx xxxxxxxxx v xxxxxxx EINECS |
xxxx xxxxxxxxxx |
x |
x |
x |
x |
|
|
|
x |
|
x |
x |
x |
|
|
|
|
|
|
|
950 |
alkyltrimethylamonium-chloridy, -xxxxxxx xxxx -methyl-sulfáty) (xxxxxx (C8-C18) xxxxxxxx x nenasycené, odvozené xx mastných xxxxxxx xxxx, kokosového oleje x sójového xxxxx) (XXXX) |
XX |
xxxx látek uvedených x seznamu EINECS |
není xxxxxxxxxx |
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
948 |
xxxxxx(xxxxx)xxxxxxxxxxxxxxx-xxxxxxxx, -bromidy xxxx -xxxxxxxxx) (alkyly (X8-X22) xxxxxxxx x xxxxxxxxxx, xxxxxxxx xx xxxxxxxx xxxxxxx loje, xxxxxxxxxx xxxxx a sójového xxxxx) (XXX) |
XX |
xxxx látek xxxxxxxxx x xxxxxxx XXXXXX |
xxxx xxxxxxxxxx |
x |
x |
x |
x |
|
|
|
x |
|
x |
x |
x |
|
|
|
|
|
|
|
849 |
3-xxxxxxxxxxxx-(1X,3XX)-2,2-xxxxxxxx-3-(2-xxxxxxxxxx-1-xx-1-xx)xxxxxxxxxxx-1-xxxxxxxxxx (x-xxxxxxxxx) |
XX |
xxxx xxxxxxxxxx |
188023-86-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
1001 |
alkyl(C12-C16)benzyl(dimethyl)amonium-chloridy (xxxx xxx xxxxx xxxxxxxxx pod xxxxxxx 671) |
XX |
xxxx xxxxxxxxxx |
není relevantní |
x |
x |
x |
x |
|
|
|
x |
|
x |
x |
x |
|
|
|
|
|
x |
|
1002 |
alkyl(C12-C18)benzyl(dimethyl)amonium-chloridy(jiné xxx xxxxx spadající xxx položku 667) |
XX |
xxxx xxxxxxxxxx |
xxxx xxxxxxxxxx |
x |
x |
x |
x |
|
|
|
|
|
x |
x |
x |
|
|
|
|
|
x |
|
1003 |
xxxxx(X12-X18)(xxxxxxxxxxx)xxxxxxxxxxxxxxx- xxxxxxxx (xxxx xxx xxxxx xxxxxxxxx pod položku 725) |
XX |
xxxx xxxxxxxxxx |
xxxx relevantní |
x |
x |
x |
x |
|
|
|
|
|
x |
x |
x |
|
|
|
|
|
x |
|
1005 |
alkyl(C12-C14)benzyl(dimethyl)amonium-chloridy (xxxx xxx xxxxx xxxxxxxxx xxx xxxxxxx 724) |
XX |
xxxx xxxxxxxxxx |
xxxx xxxxxxxxxx |
x |
x |
x |
x |
|
|
|
|
|
x |
x |
x |
|
|
|
|
|
x |
|
1006 |
xxxxxxxxxxxxxx xxxx xxxxxxxxxx stříbro, xxxxx, xxxxxx x xxx |
XX |
xxxx xxxxxxxxxx |
398477-47-9 |
|
x |
|
|
|
|
x |
|
x |
|
|
|
|
|
|
|
|
|
|
1009 |
dialkyl(C8-C10)dimetylamonium-chloridy (xxxx xxx látka xxxxxxxxx xxx položku 673) |
XX |
xxxx xxxxxxxxxx |
xxxx xxxxxxxxxx |
x |
x |
x |
x |
x |
x |
|
|
|
x |
x |
x |
|
|
|
|
|
|
|
1011 |
xxxxx(xxxxxxxxx)xxxxxxx-xxxxxxxx (alkyl xxxxxxx xx xxxxxxxx xxxxxxx xxxxxxxxxx oleje) (xxxx než látka xxxxxxxxx xxx xxxxxxx 635) |
XX |
xxxx xxxxxxxxxx |
xxxx xxxxxxxxxx |
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
1012 |
hlinitokřemičitan xxxxx, xxxxxxxx a xxxxxxxxx komplex/stříbrno-zinečnatý zeolit |
XX |
xxxx xxxxxxxxxx |
130328-20-0 |
|
x |
|
|
|
|
x |
|
x |
|
|
|
|
|
|
|
|
|
|
598 |
(±)-1-(β-xxxxxxxx-2,4-xxxxxxxxxxxxxxxxx)xxxxxxxx (imazalil technický) |
XX |
xxxxxxxxx xx xxxxxxx rostlin |
73790-28-0 |
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
XXXXXXX XXX
Xxxxx
|
Xxxx xxxxxxxxx |
Xxxxx xxx xxxxxxxxxx hodnotící zprávy xxxxx xx. 6 xxxx. 3 xxxx. x) |
Xxxxx xxx xxxxxxxx xxxxxxxx xxxxxxxxxx xxxxx xx. 7 xxxx. 2 xxxx. x) |
|
8, 14, 16, 18, 19 x 21 |
31.12.2015 |
31.3.2016 |
|
3, 4 x 5 |
31.12.2016 |
31.3.2017 |
|
1 x 2 |
31.12.2018 |
31.3.2019 |
|
6 x 13 |
31.12.2019 |
31.3.2020 |
|
7, 9 a 10 |
31.12.2020 |
31.3.2021 |
|
11, 12, 15, 17, 20 a 22 |
31.12.2022 |
31.9.2023 |